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ABSTRACT 
Patients with bacteraemia have viable bacteria in the blood. A part of the patients 
with bacteraemia have sepsis, but bacteraemia is not mandatory in sepsis by 
definition. The day 7 and day 28 all-cause mortality in patients with these infections 
is high. However, this all-cause mortality does not express how lethal the infection 
itself is. It has been known that underlying diseases have a role in the deaths of 
patients with bacteraemia and sepsis, but the magnitude of this role has hardly been 
studied at all.  
Studies on biomarkers are conducted to get new tools for diagnostics or 
indicators for prognosis, for example. Studies on biomarkers also elucidate the 
pathogenesis of diseases. Some studies have shown cell-free DNA (cfDNA) as a 
prognostic biomarker, but it has not yet been studied against, or in combination with, 
a prognostic score qSOFA (quick sequential organ failure assessment). Evidence has 
also accumulated that cfDNA is a major factor in the pathogenesis of disseminated 
intravascular coagulation (DIC).  
The proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme is known for 
its role in cholesterol metabolism. There are two antibodies, alirocumab and 
evolocumab, that are in use to lower cholesterol. Recent studies have indicated that 
PCSK9 also regulates the clearance of lipopolysaccharides (Gram-negative bacteria) 
and lipoteichoic acid (Gram-positive bacteria), and hence researchers are already 
recruiting patients to trials with the antibodies. However, studies on the level of this 
enzyme in infections are still scarce. 
Against this background, the aim of this study was to elucidate the role of 
underlying diseases in deaths after a bacteraemia (Study I), to determine the role of 
plasma cfDNA in predicting prognosis in bacteraemia (Study II), and to assess the 
level of PCSK9 in bacteraemic patients and to determine the level in patients with 
severe disease or in relation to day 7, day 28, and day 90 deaths (Study III).  
This cohort study involved 497 cases (484 patients) with bacteraemia gathered 
from the emergency department of Tampere University hospital during the years 
2012-2014. The clinical data and the blood samples were gathered prospectively. The 
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biomarker analysis was done from 481 cases. Day 7, day 28, and day 90 mortality 
was 9%, 14%, and 20%, respectively. 
In Study I, a new method was developed to categorise the patients that died by 
day 90 into three groups. By clinical judgement, the deaths of Group 1 patients were 
bacteraemia-related, and the patients did not have a rapidly fatal underlying disease. 
The deaths of Group 2 patients were also bacteraemia-related, but the patients had 
a rapidly fatal underlying disease. The deaths of Group 3 patients were only 
underlying disease related. The result was 16 patients (16% of all deaths) in Group 
1, 45 patients (46%) in Group 2 and 37 patients (38%) in Group 3. The most 
common underlying disease in Groups 2 and 3 was solid cancer with metastasis. It 
was also found that death by day 7 does not equal that the death is directly related 
to bacteraemia as 66% of deaths by day 7 belonged to Group 2 and 3.  
In Study II, the median level of cfDNA on day 0 was 1.38 μg/ml. The median 
level was significantly higher on day 0 in those who died by day 7 compared to those 
who survived (p<0.001). CfDNA had an area under curve (AUC) of 0.77 (95% 
Confidence Interval (CI) 0.69 to 0.85) in predicting death by day 7. QSOFA having 
AUC 0.77 (95% CI 0.70 to 0.85) was comparable with cfDNA, but C-reactive 
protein (CRP) had an AUC of only 0.52 (95% CI 0.43 to 0.60). Patients with cfDNA 
level of ≥1.69 μg/ml combined with qSOFA score ≥2 had an odds ratio of 20 of 
death by day 7. Amongst the five cases with the highest cfDNA levels, there were 
three patients with severe DIC. 
In Study III, the median level of PCSK9 on day 0 was 376 ng/ml, which is a 
significantly higher level than in a control group of healed bacteraemia patients 
(p<0.001). Patients that died by day 7 and day 28 had a significantly lower level of 
day 0 PCSK9 (p=0.022 and p=0.001, respectively) than those who survived. There 
was no statistically significant difference in the level of PCSK9 between Gram-
positive or Gram-negative bacteria (p=0.499). PCSK9 level had a significant positive 
correlation with CRP (p<0.001).  
In conclusion, the role of the underlying diseases in deaths of patients with 
bacteraemia was found to be significant, cfDNA is, in contrast with CRP, a 
prognostic biomarker, and the level of PCSK9 is elevated in patients with 
bacteraemia, but less elevated in those that died by day 7 and day 28.  
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TIIVISTELMÄ 
Bakteremiassa potilaalta löydetään eläviä bakteereita verenkierrosta. Osalla 
bakteremiapotilaista on myös sepsis, mutta sepsiksessä ei välttämättä tarvitse olla 
bakteremiaa. Molemmissa näistä päivän 7 ja päivän 28 kuolleisuus on kirjallisuuden 
mukaan korkea. Kuolleisuutta koskevissa tutkimuksissa ei kuitenkaan ole huomioitu 
erikseen pitkäaikaissairauksien vaikutusta. Pitkäaikaissairauksien tiedetään 
vaikuttavan infektiokuolleisuuteen, mutta pitkäaikaissairauksien ja infektioiden 
keskinäistä suhdetta on kuitenkin tutkittu vähän. 
Sepsiksen diagnostiikan ja ennusteen arvioinnin apukeinoina on tutkittu erilaisia 
verenkierrosta mitattavia biologisia merkkiaineita. Biologisten merkkiaineiden 
tutkimus on lisännyt myös ymmärrystä sairauksien patogeneesistä. Muutamat 
tutkimukset ovat osoittaneet soluvapaalla DNA:lla (cell-free DNA, cfDNA) olevan 
kuolleisuutta ennustavaa arvoa, mutta tutkimuksia, joissa sitä olisi verrattu sepsiksen 
ennustetta mittaavaan pisteytykseen, qSOFA:n (quick Sequential Organ Failure 
Assessment), ei ole aiemmin tehty. Viimeisimpien tutkimusten mukaan cfDNA on 
myös merkittävä tekijä yleistyneen hyytymishäiriön (DIC:n) patogeneesissä. 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) –entsyymillä on rooli 
kolesteroliaineenvaihdunnassa, ja kaksi siihen vaikuttavaa vasta-ainetta, alirokumabi 
ja evolokumabi, ovat käytössä kolesterolilääkkeinä. Viimeaikaiset tutkimukset ovat 
osoittaneet saman entsyymin säätelevän myös gram-negatiivisten bakteereiden 
hajoamisessa syntyvän lipopolysakkaridin ja gram-positiivisten bakteereiden 
lipoteikkohapon poistamista verenkierrosta. Tästä syystä molemmilla yllä mainituilla 
lääkkeillä on jo aloitettu tutkimukset sepsispotilailla, vaikka tutkimuksia tämän 
entsyymin veripitoisuuksista infektiopotilailla on vasta vähän.  
Tätä taustaa vasten tutkimuksen tavoitteena oli selvittää pitkäaikaissairauksien 
osuutta bakteremian jälkeisessä kuolleisuudessa (Tutkimus I), tutkia 
bakteremiapotilailla cfDNA:n ennustearvoa (Tutkimus II) ja selvittää PCSK9-
entsyymin pitoisuuksia verenkierrossa bakteremiapotilailla sekä niiden korrelaatiota 
bakteremian vaikeusasteeseen ja potilaan ennusteeseen (Tutkimus III).  
Kyseessä oli kohorttitutkimus, jonka aineisto muodostui 497:stä 
bakteremiatapauksesta 484:llä eri potilaalla. Bakteremiapotilaat olivat olleet 
Tampereen yliopistollisen sairaalan päivystyspoliklinikalla vuosina 2012-2014. 
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Kliininen aineisto sekä verinäytteet kerättiin prospektiivisesti. Biomarkkereita 
analysoitiin 481:ltä tapaukselta. Kuolleisuus oli päivään 7 mennessä 9%, päivään 28 
mennessä 14% ja päivään 90 mennessä 20%. 
Tutkimuksessa I kehitettiin metodi, jossa infektiolääkärit jaottelivat 90 päivän 
sisällä bakteremiasta kuolleet potilaat kolmeen ryhmään. Ensimmäiseen ryhmään 
jaoteltiin ne potilaat, joiden kuoleman he katsoivat liittyvän bakteremiaan ja joilla 
olisi ollut yli puolen vuoden elinaikaennuste ilman bakteremiaan sairastumista. 
Ryhmään kaksi jaoteltiin ne potilaat, joiden kuolema liittyi bakteremiaan, mutta 
joiden ennuste olisi joka tapauksessa ollut alle puoli vuotta. Kolmanteen ryhmään 
jäivät ne bakteremiapotilaat, joiden kuolema katsottiin liittyvän vain 
pitkäaikaissairauksiin. Ryhmään yksi jaoteltiin 16 potilasta (16% kaikista kuolleista), 
ryhmään kaksi 45 potilasta (46%) ja ryhmään kolme 37 potilasta (38%). Yleisin 
pitkäaikaissairaus ryhmissä 2 ja 3 oli etäpesäkkeinen pahanlaatuinen kasvain. 
Tutkimuksessa todettiin myös, ettei edes päivään 7 mennessä tapahtuvia kuolemia 
voida pitää pelkästään bakteremiasta johtuvana vaan tässäkin ryhmät 2 ja 3 
muodostivat enemmistön (66%). 
Tutkimuksessa II bakteremiapotilaiden päivystyspoliklinikalla otettujen (päivä 0) 
cfDNA:n arvojen mediaani oli 1,38 μg/ml. Mediaani oli tilastollisesti merkittävästi 
korkeampi päivään 7 mennessä menehtyneillä kuin henkiin jääneillä (p<0,001). 
CfDNA:n AUC-arvo (area under curve) päivään 7 mennessä tapahtuvan 
menehtymisen ennustamisessa oli 0,77 (95% luottamusväli (LV) 0,69-0,85). 
QSOFA:lla oli samankaltainen ennusterarvo (AUC 0,77, 95% LV 0,70-0,85), mutta 
C-reaktiivisella proteiinilla (CRP:llä) AUC oli vain 0,52 (95% LV 0,43-0,60). Jos 
potilaan cfDNA oli yli 1,69 μg/ml ja samanaikaisesti qSOFA-pisteytys 2 tai yli, 
potilaan vetosuhde (odds ratio) menehtymisestä päivään 7 mennessä oli 20-kertainen 
verrattuna niihin, joilla sekä cfDNA-taso että qSOFA-pisteytys olivat matalampia. 
Viiden korkeimman cfDNA-arvon saaneiden joukossa oli kolme vaikean DIC-
komplikaation saanutta potilasta. 
Tutkimuksessa III bakteremiapotilaiden päivystyspoliklinikalla otettujen (päivä 0) 
PCSK9:n arvojen mediaani oli 376 ng/ml, mikä on tilastollisesti merkitsevästi 
korkeampi kuin bakteremiasta parantuneilla potilailla. Sekä päivään 7 että päivään 28 
mennessä menehtyneillä oli muita bakteremiapotilaita tilastollisesti merkitsevästi 
alhaisempi PCSK9:n taso (p=0,022 ja p=0,001, tässä järjestyksessä). Gram-
positiivisten ja gram-negatiivisten bakteremioiden välillä ei ollut tilastollissesti 
merkitsevää eroa PCSK9:n pitoisuuksissa (p=0,499). PCSK9:n pitoisuuksilla oli 
merkitsevä positiivinen korrelaatio CRP:n pitoisuuksien kanssa. (p<0.001).  
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Yhteenvetona voidaan sanoa pitkäaikaissairauksilla olevan merkittävä rooli 
bakteremian jälkeisessä kuolleisuudessa. Lisäksi cfDNA:n kyky ennustaa 
kuolleisuutta bakteremiapotilailla osoittautui hyväksi, toisin kuin CRP:llä. PCSK9 
nousi bakteremian yhteydessä, mutta sen pitoisuudet olivat matalammat päivään 7 ja 
28 mennessä menehtyneillä kuin eloonjääneillä. 
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1 INTRODUCTION 
Bacteraemia is the presence of viable bacteria in the blood (Bone et al. 1992). Patients 
with bacteraemia have sepsis if the bacteraemia has evoked a life-threating response 
from the immune system, but bacteraemia is not mandatory in the definition of 
sepsis (Singer et al. 2016). Moreover, those patients that fulfil the current definition 
of sepsis are on average in a slightly worse shape than bacteraemia patients, and may 
require care in high dependency units (HDUs) or intensive care units (ICUs) (Rhodes 
et al. 2017). This is due to the fact that the current definition of sepsis include patients 
that have an organ failure as did the old definition of severe sepsis (Singer et al. 
2016). Nevertheless, most patients with bacteraemia have an infection for which the 
care, at least at the start, is reasonable to be given in hospitals.  
There is medical literature about bacteraemia, but sepsis is far more abundantly 
covered in the literature, especially when the topic is the treatment of infections. In 
studies conducted mainly in ICUs, mortality in severe sepsis is reported to be up to 
50% (Bernard et al. 2001, Peake et al. 2014, Yealy et al. 2014, Freund et al. 2017) 
These figures originate often from randomised controlled trials in which the in-
hospital or day 28 mortality of the control group would be the mortality to sepsis. 
These figures represent often all-cause mortality, and the role of sepsis itself vs. the 
role of the underlying diseases in the cause of death is seldom estimated. 
Plasma cell-free DNA (cfDNA) derives from cellular necrosis, apoptosis, and 
lysis (Rhodes and Cecconi 2012, Hou et al. 2016). There is also a secreted form, 
neutrophil extracellular traps (NETs), that has been shown to have a crucial role in 
thrombus initiation and progression (Fuchs et al. 2010, Martinod and Wagner 2014, 
Duplessis et al. 2018). Plasma cfDNA level is low in healthy individuals, but the level 
has been shown to rise in various conditions such as trauma, cancer, stroke, 
myocardial infarction, and sepsis (Wijeratne et al. 2004, Spindler et al. 2015, Ahmed 
et al. 2016, Clementi et al. 2016). As the level rises in various conditions, studies on 
the role of cfDNA in discriminative diagnostics are few, but several studies have 
concentrated on its use as a prognostic biomarker. CfDNA may have value in 
predicting the mortality of septic ICU patients (Zeerleder et al. 2003, Rhodes et al. 
2006, Saukkonen et al. 2008, Dwivedi et al. 2012), but the value in prognosis of 
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patients with infection outside ICUs has been studied less (Moreira et al. 2010, 
Huttunen et al. 2011a). 
The Proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme is known for 
its role in cholesterol metabolism (Seidah and Prat 2012, Spolitu et al. 2019). Two 
PCSK9 targeting antibodies, alirocumab and evolocumab, are currently used to treat 
statin-resistant or statin-intolerant hypercholesterolemia patients (Robinson et al. 
2015, Sabatine et al. 2017). However, PCSK9 does not only regulate cholesterol 
metabolism, but regulates also the clearance of lipopolysaccharides (Gram-negative 
bacteria) and lipoteichoic acid (Gram-positive bacteria) (Grin et al. 2018). Before the 
current study, the level of PCSK9 in patients with infection has been evaluated in 
two studies (Walley et al. 2014, Boyd et al. 2016). These studies have indicated that 
the level would be higher than average in patients with more severe disease. Two 
clinical trials are ongoing to evaluate whether PCSK9 inhibiting antibodies could be 
used to treat patients with sepsis (clinicaltrials.gov). So far, no other therapeutic 
interventions on endotoxins have succeeded in meeting their objectives (Angus et 
al. 2000, Ankawi et al. 2018, Dellinger et al. 2018). 
In the present study, the role of sepsis and the role of underlying diseases in 
deaths after a bacteraemia were evaluated. The value of cfDNA level in the prognosis 
of patients with bacteraemia, as well as the level of PCSK9 to the severity of the 
infection were also assessed.  
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2 REVIEW OF THE LITERATURE 
2.1 Bacteraemia and sepsis 
2.1.1 Definitions 
Bacteraemia is the presence of alive and reproducible bacteria in the circulation 
(Bone et al. 1992). Other almost identical terms are bloodstream infection and 
septicaemia, but these also include the presence of yeasts in the blood (also known 
as fungemia). Contaminants, i.e. bacteria deriving from the skin puncture site, are 
excluded from bacteraemia studies. Before 2016, the definition of sepsis was the 
systemic inflammatory response syndrome (SIRS) in response to an infection (Bone 
et al. 1992, Levy et al. 2003) (Table 1). SIRS was the presence of two or more of the 
following: abnormal heart rate, body temperature, respiratory rate, and white blood 
cell count. At that time, patients with sepsis were categorized having severe sepsis if 
they had an organ dysfunction and septic shock if they had a persistent low blood 
pressure despite adequate administration of fluids. 
The new definitions of sepsis and septic shock were published in 2016 (Singer et 
al. 2016). This SEPSIS-3 criterion abandoned SIRS and the definition of sepsis 
changed to “life-threatening organ dysfunction caused by a dysregulated host 
response to infection”. The term severe sepsis was also abandoned and serum lactate 
level was added to the definition of septic shock (Shankar-Hari et al. 2016). To fulfil 
the criteria of organ dysfunction, patients need to have an acute change in total 
Sequential (Sepsis-related) Organ Failure Assessment (SOFA) score ≥2 points 
consequent to the infection (Vincent et al. 1996, Singer et al. 2016). Furthermore, a 
new score, qSOFA, was introduced as a quick way to find patients who are in risk of 
dying. In developing this score, patients that had an alteration in mental status, 
systolic blood pressure ≤100 mm Hg, or respiratory rate ≥22/min were found to 
have a higher in-hospital mortality (Seymour et al. 2016). If a patient fulfils two or 
three of these criteria (positive qSOFA score), the patient has a risk of death that is 
equivalent to the raise of SOFA score of 2 points or more (Freund et al. 2017). 
Nevertheless, in a research setting, positive qSOFA in patient with infection does 
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not necessitate that the patient has sepsis. Only those patients with infection that 
fulfil the SOFA criteria have sepsis by definition even though SOFA is rarely used 
in emergency departments (EDs) and wards (Singer et al. 2016, Keeley et al. 2017).  
Neither the old nor the new definition of sepsis necessitate that sepsis patients 
should have a bacteraemia or that all patients with bacteraemia would have sepsis. 
Nevertheless, before Sepsis-3 definition, in practise all patients with bacteraemia had 
also sepsis (Jones and Lowes 1996, Coburn et al. 2012, Vincent et al. 2016a). The 
new definition of sepsis is based on organ dysfunction which all patients with 
bacteraemia don’t have (Singer et al. 2016, Ljungstrom et al. 2017). 
Table 1.  The old and the new definition of sepsis 
 SEPSIS SEVERE SEPSIS SEPTIC SHOCK 
The old definition (Sepsis-2) ≥2 SIRS criteria met and 
(suspected) infection 
Criteria:  
Tachycardia 
Tachypnea 
Fever/hypothermia 
Leucopenia/leucocytosis 
Sepsis and organ failure Persistent hypotension 
The new definition (Sepsis-3) (Suspected) infection and 
organ failure (Increase of 
≥2 SOFA points) 
Not applicable Persistent hypotension and 
hyperlactatemia 
2.1.2 Incidence 
According to the report of the Finnish National Institute for Health and Welfare, 
there were more than 17 000 episodes of bacteraemia in the year 2017 in Finland, 
being 1.7 times more than the annual number of episodes in the year 2008 (Jaakola 
et al. 2018). In year 2018 there was 1542 patients with positive blood culture in 
Tampere University Hospital (data from SAI-registry). In the United States, there 
are approximately 200 000 episodes of bacteraemia each year, with an incidence of 
about 10 per 1000 hospital admissions (Coburn et al. 2012). The incidence of sepsis 
in all patients of the Finnish EDs is not known. However, between 2007 and 2012, 
the incidence of severe sepsis in patients transferred to ICU has risen from 38 per 
100 000 adult population to 60 per 100 000 (Karlsson et al. 2007, Poukkanen et al. 
2013). The incidence of sepsis in the United States and other parts of the western 
world has also increased (Angus et al. 2001, Martin et al. 2003). 
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There are no studies giving definite answers as to why these incidences have 
changed, but at least in Finland the taking of blood cultures as a part of clinical 
evaluation of patients has increased (Skogberg et al. 2008). Furthermore, the aged 
(>65 years) account for the majority of all episodes of both bacteraemia and sepsis 
(Blanco et al. 2008, Esper and Martin 2009, Kaukonen et al. 2014, Jaakola et al. 2018) 
and thus the aging of the population might have led to the change. Other 
explanations could be immunosuppression and better awareness of the possibility of 
sepsis (Rintala and Karlsson 2017). 
The incidence of positive blood cultures among patients with sepsis is dependent 
on the severity of the infection. In one study, a positive culture was found in 17% of 
patients with a SIRS-positive sepsis, in 25% with severe sepsis, and in 69% of 
patients with septic shock (Rangel-Frausto et al. 1995). In different studies, the 
proportion of community-acquired vs. hospital-acquired bloodstream infections has 
been around 50% (Diekema et al. 2003, Shorr et al. 2006). These two differ in 
causative organisms, patient groups and prognosis. (Diekema et al. 2003, Gaynes and 
Edwards 2005). 
2.1.3 Pathophysiology 
Bacterial structures are triggers for host response. Macrophages are the major cells 
responsible for innate immunity by recognizing and binding to microbial 
components (i.e. pathogen associated molecular patterns, PAMPs). They release 
proinflammatory cytokines inviting additional inflammatory cells, for example 
leucocytes. Anti-inflammatory cytokines have a role of limiting the response. Host 
response is capable of clearing a limited number of bacteria, and sepsis occurs when 
the response is both generalized and excessive. (Aird 2003, Cinel and Dellinger 2007, 
Chen and Nunez 2010) 
The precise mechanism of cellular injury in sepsis is not known. Tissue ischemia, 
cytopathic injury and an altered rate of apoptosis have been proposed to be at least 
part of the explanation (Angus and van der Poll 2013). This cellular injury causes the 
release of danger-associated molecular patterns (DAMPs) that, in addition to 
PAMPs, are recognised by the receptors on the surface of immune cells. (Hotchkiss 
et al. 2001, Janeway and Medzhitov 2002, Chen and Nunez 2010, Zhang et al. 2010). 
The complement system is another important factor in innate immunity. It has a 
role in defending against pyogenic bacterial infection, disposing of the products of 
inflammatory injury and immune complexes, and bridging adaptive and innate 
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immunity (Walport 2001). Inhibition of complement cascade has decreased sepsis 
mortality in several animal models (Riedemann et al. 2002, Liu et al. 2007), but this 
has not been adapted into clinical use. 
2.1.4 Blood culture findings 
Among adult patients in Finland, Gram-negative bacteria are causative 
microorganism in ca. 50% of all bacteraemias and Gram-positives in ca. 45%. 
Anaerobes constitute ca. 4% of cases (Jaakola et al. 2018). The vast majority (71 %) 
of positive blood cultures are detected in aged persons. The most common 
microorganism in Finland is Escherichia coli (23% of all bacteraemia) followed by 
Staphylococcus aureus (13%) and Klebsiella (6%) (Jaakola et al. 2018). These figures 
are approximately the same elsewhere in the developed world (Cisterna et al. 2001, 
Ortega et al. 2007).  
2.1.5 Risk factors 
Some of the known risk factors for bacteraemia and sepsis are age, i.e. being infant 
or aged, trauma, and hospitalization. Other risk factors include various diseases and 
treatments such as AIDS, diabetes, asplenia, malignancies and treatments for 
malignancies (Williams et al. 2004, Martin et al. 2006, Wang et al. 2012, Torres et al. 
2015, Novosad et al. 2016). These risk factors weaken the body’s natural borders 
such as the skin or the intestine or they weaken the immune system or both. 
Furthermore, there are numerous genetic variations (mostly single nucleotide 
polymorphisms, SNPs) that are associated with susceptibility to infection (Kenney 
et al. 2017). These SNPs are in genes that encode various cell surface receptors, 
cytokines and enzymes of the immune defence. However, in clinical practice, genetic 
sequencing of a patient with infection is uncommon.  
2.1.6 Clinical manifestations 
The majority of bacteraemic patients have fever, but this also reflects the fact that 
fever is a common reason why clinicians have originally decided to take the blood 
cultures (Coburn et al. 2012). The presence of shaking chills (rigors) has been shown 
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to be independently associated with positive blood culture (Lee et al. 2012). Absence 
of fever has been associated with increased mortality (Yahav et al. 2016). 
The current definition of sepsis is based on a score that measures organ 
dysfunction (Singer et al. 2016). Hence the clinical manifestations of sepsis patients 
represent more severe types of infection than patients with sepsis by the old 
definition used to have (Abraham 2016). The classical signs and symptoms of sepsis 
are fever, increased heart rate, tachypnea and hypotension. Lactatemia, metabolic 
acidosis, oliguria and skin manifestations are possible (Gotts and Matthay 2016). 
Patients with bacteraemia may have all of the aforementioned signs and symptoms 
or only some of them. Especially the aged and other patients with vasculopathy of 
the brain commonly have an altered mentation. The aged may lack fever and the 
only sign of septic infection could be poor condition. (Angus and van der Poll 2013, 
Yahav et al. 2016, Rintala and Karlsson 2017). 
Sepsis affects a number of laboratory values. Leucocytosis or leucopenia, 
thrombocytopenia, creatinine increase, elevated C-reactive protein (CRP) or 
procalcitonin, hyperbilirubinemia, hyperlactatemia, acidosis, and elevation of INR or 
aPTT are all possible, but none of these is specific to infection (Angus and van der 
Poll 2013, Dellinger et al. 2013).  
When the generalized and excessive response to infection has started, all organs 
are in risk of dysfunction. Vasodilatation and other factors lead to hypotension 
which in turn leads to tissue hypoperfusion and ischemia. Cardiopathy, renal failure, 
liver failure and haematological disturbances are all common in the most severe types 
of sepsis. If a patient has a progressive disturbance of homeostasis, the entity is called 
multiple organ dysfunction syndrome (MODS) or multiple organ failure (MOF) 
having a high mortality (Marshall et al. 1995).  
2.1.7 Treatment 
The more severe the infection, the more important the timing of the antibiotic is 
(Kumar et al. 2006, Seymour et al. 2017). Bacteraemic pyelonephritis may be treated 
with oral fluoroquinolones (Peterson et al. 2008, Sandberg et al. 2012), but patients 
with sepsis are initially treated with intra-venous antibiotic (Gotts and Matthay 2016, 
Rintala and Karlsson 2017). The choice of antibiotic is based on multiple different 
factors such as the focus, underlying diseases, the state of immunosuppression and 
carriage of resistant microbes. Local antibiotic guidelines should be followed. 
Empirical treatment of sepsis with unknown focus should cover the possibility of 
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both Gram-negatives and Gram-positives (Savage et al. 2016, Rhodes et al. 2017). 
Follow-up blood cultures should be taken in certain circumstances, such as in 
Staphylococcus aureus bacteraemia (Holland et al. 2014, Canzoneri et al. 2017).  
A patient with life-threatening infection needs fluid resuscitation (balanced salt 
solutions) (Sethi et al. 2018). In general, mean arterial pressure should be kept over 
65 mmHg (Rivers et al. 2001, Vincent et al. 2016b). Glucocorticoid therapy should 
not be given routinely, but current guidelines recommend its use in septic shock if 
the patient is not responding to vasopressor treatment (Rhodes et al. 2017). An 
ongoing glucocorticoid treatment should not be stopped, particularly for those with 
longstanding high doses (van der Goes et al. 2014).  
2.2 Prognosis in bacteraemia and sepsis 
2.2.1 Overview of the prognosis and the problems with the estimates 
The prognosis in sepsis depends on the multitude and severity of organ dysfunction. 
Even though there has been improvement in managing the condition, the all-cause 
in-hospital mortality for severe sepsis both in Finland and the rest of the western 
world is 20% to 30% (Angus et al. 2001, Kumar et al. 2011, Poukkanen et al. 2013, 
Kaukonen et al. 2014, Kaukonen et al. 2015). After discharge, these patients still 
carry an increased risk of death (Perl et al. 1995, Nesseler et al. 2013, Linder et al. 
2016). In a Finnish study on severe sepsis patients treated in ICU, in-hospital 
mortality was 28%, blood cultures were taken from 68% of patients and cultures 
were positive in 40% (Karlsson et al. 2007). Is some studies, in-hospital and day 30 
mortality to bacteraemia have been approximately the same or slightly less than 
mortality to severe sepsis (Alberti et al. 2003, Coburn et al. 2012, Kethireddy et al. 
2018, Meier et al. 2018). In one study, cases with sepsis that had a positive culture 
had higher day 28 mortality than cases with culture-negative sepsis (Nannan Panday 
et al. 2019). 
The mortality of sepsis varies depending on the study material. In one study from 
the United States, mortality based on administrative claims data was 15% to 140% 
higher (range 168 000-381 000 deaths per year) than annual estimates generated 
using death certificate data (range 146 000-159 000 deaths per year) (Epstein et al. 
2016). Both figures are still rough estimates as both of the data have numerous 
limitations. Sepsis is a consensus definition with no confirmatory diagnostic test 
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(Chen et al. 2019a). In clinical practise, the diagnosis is not based on scores, but on 
evidence of infection and clinical judgement (Lever and Mackenzie 2007). Moreover, 
death certificates have both the underlying and the immediate cause of death (CDC 
2016). There is no consensus on whether sepsis mortality should be equal with sepsis 
in the death certificate as both of these causes, or either one of them is enough. In 
addition, in clinical trials the mortality depends on the inclusion and exclusion 
criteria, and hence the figures differ. 
2.2.2 Virulence and other factors influencing the outcome 
The clinical manifestations of bacteraemia are varied. Transient bacteraemia are 
possible after dental procedures (Wilson et al. 2007, Horliana et al. 2014) or other 
operations affecting mucous membranes. Most of these bacteraemia are probably 
undetected as they do not have clinical relevance. The other end of clinical 
manifestation is a patient with septic shock and high mortality. This difference in 
clinical manifestation is multi-factorial and explanations lie both on patient 
characteristics and bacterial factors, such as bacterial virulence (Diard and Hardt 
2017). As an example, Streptococcus pneumoniae, Streptococcus pyogenes, Capnocytophaga 
canimorsus, Neisseria meningitis and Staphlylococcus aureus are more virulent than bacteria 
such as Enterococcus faecium (Gao et al. 2018). Bacteraemias caused by methicillin-
resistant Staphylococcus aureus have worse prognosis over methicillin-sensitive S. aureus 
infection, and polymicrobial infections over monomicrobial infection (Sogaard et al. 
2011, Labelle et al. 2012, Jokinen et al. 2017) 
Comorbidities and the type of infection are known determinants of outcome. 
Comorbidities associated with poor prognosis include diseases such as liver disease, 
alcoholism, immunosuppression and cancer (Williams et al. 2004, Wang et al. 2012, 
Torres et al. 2015). The prognosis is worse for nosocomial infection than community 
acquired infections (Shorr et al. 2006). Moreover, the site of infection plays a role. 
As an example, sepsis originating from the urinary tract has a low mortality, but the 
mortality exceeds 75% in sepsis associated with ischemic bowel (Labelle et al. 2012). 
2.2.3 Statistical methods to find the sepsis-caused deaths 
In sepsis studies, there are two different statistical methods that could be of help to 
get closer to the attributable fraction of sepsis-caused deaths. The first is to do a 
multi-variable logistic regression model, and include variables such as patient age, 
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length of stay, re-admission to hospital, and number of diagnoses. One example of 
this is an Irish study that calculated the attributable mortality of hospital-acquired 
bloodstream infections (Brady et al. 2017). They found the highest attributable 
mortality for E. faecium and the lowest attributable mortality for E. coli. The other is 
propensity-matched groups, and it is also used to find attributable mortality 
(Shankar-Hari et al. 2018, Kadri et al. 2019). In both of these methods the results are 
dependent on the variables and their ability to standardise the groups.  
2.2.4 The use of scores and indexes in the prognosis 
The new definition of sepsis is based on calculations on the prognosis among 
patients with infection (Seymour et al. 2016). Especially in the developing of the new 
score qSOFA, the task force tried to find as simple a calculator as possible that has 
high predictive validity for in-hospital mortality among patients with suspected 
infection outside ICU. In their patient cohort, they calculated an area under curve 
(AUC) of 0.81 (95% CI 0.80-0.82). However, in a recent meta-analysis of qSOFA, 
the median AUC for in-hospital mortality was not that good (0.68, 95% CI 0.65-
0.71) (Lo et al. 2019). The prognostic accuracy of qSOFA has also been questioned 
in geriatric patients (Bastoni et al. 2019).  
There have already been numerous different scores to predict the mortality of 
both sepsis patients and ED/ICU patients in general. As an example, National Early 
Warning Score (NEWS) has had better predictive validity than qSOFA (Churpek et 
al. 2017a, Churpek et al. 2017b, Brink et al. 2019). However, none of these scores 
developed so far are as easy to calculate as qSOFA. 
The importance of the underlying diseases in sepsis mortality has been long 
known. The McCabe classification was created already in the 1960s to categorise 
bacteraemia patients by their prognosis (McCabe and Jackson 1962). Patients are 
categorized whether they a have rapidly fatal, ultimately fatal or non-fatal underlying 
disease. This old classification has been shown to be a better predictor of mortality 
in patients suspected of Gram-negative sepsis than the Acute Physiology and 
Chronic Health Evaluation II (APACHE II) score (Perl et al. 1995). This 
classification also has a variation designed for ICU patients, the Sabadell score 
(Fernandez et al. 2006). 
Scoring systems like Charlson Comorbidity Index (Charlson et al. 1987) or 
Chronic Disease Score (Von Korff et al. 1992) have tried to adjust the underlying 
diseases and conditions to get a better evaluation of the mortality. The problem with 
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these scores is that they should be validated regularly as the prognosis of the different 
underlying diseases changes over time. For example, the prognosis of an HIV patient 
has changed dramatically since 1987. There are variations of the original Charlson 
Index, but regular validation has not happened. Furthermore, there are other scores 
that have been shown to be better predictors of mortality than the Charlson Index. 
For example, Pitt Bacteraemia Score (Korvick et al. 1991) has been shown to have 
better sensitivity and specificity than the Charlson Index (or APACHE II) (Rhee et 
al. 2009). 
2.2.5 The use of biomarkers to assess prognosis 
A working group at the National Institute of Health has defined biomarker as “a 
characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention” (NIH 2001). The most widely used infection marker in 
Finland is CRP, a short pentraxin described already in 1930s (Tillett and Francis 
1930). Nevertheless, high level of CRP is not prognostic. Among patients with 
infection, death is as possible in all levels of CRP (Zhao et al. 2013, Magrini et al. 
2014, Reichsoellner et al. 2014, Tziolos et al. 2015).  
It has been suggested that procalcitonin (PCT) should be used instead of CRP as 
it is more rapid to rise and it would be more specific (Riedel 2012, Wacker et al. 
2013). Although there are several studies concerning PCT-guided antibiotic 
discontinuation, death has been the primary outcome in only one study, and all the 
studies have had a high risk of bias (Pepper et al. 2019). This one study with death 
as primary endpoint did not show benefit in survival (Bloos et al. 2016). In another 
study, the failure of PCT level to fall by day 4 predicted day 28 mortality (Schuetz et 
al. 2017), and in a meta-analysis on survival data there was a statistically significant 
difference in the level of PCT between survivors and non-survivors (Arora et al. 
2015). 
Leukocytosis of more than 12 x 109/l, leukopenia of less than 4 x 109/l or white-
cell count with more than 10% of immature forms are examples of the inflammatory 
variables used in the suspicion of sepsis (Levy et al. 2003). Leukopenia as well as 
thrombocytopenia in sepsis has been associated with poor prognosis (Kreger et al. 
1980, Thiery-Antier et al. 2016). In one study, persistent lymphopenia on day 4 
following the diagnosis of bacteraemic sepsis predicted mortality (Drewry et al. 
2014).  
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Serum lactate is commonly elevated in patients with severe sepsis, and the 
measurement of lactate is included in the diagnosis of septic shock (Shankar-Hari et 
al. 2016). Elevated lactate is associated with poor prognosis (Mikkelsen et al. 2009, 
Casserly et al. 2015, Haas et al. 2016), and the kinetics of lactate have value as well 
(Chertoff et al. 2015). A recent study concluded that those bacteraemic patients with 
sepsis who are using metformin have a higher mean level of lactate affecting the 
prognostic accuracy (Chen et al. 2019b). 
There are around 200 other sepsis biomarkers (Sandquist and Wong 2014). One 
of the most studied ones is soluble urokinase plasminogen activator receptor 
(suPAR). This biomarker does not have much diagnostic value (Eugen-Olsen 2011), 
but has had an AUC between 0.79 and 0.84 in predicting death by day 30 (Kofoed 
et al. 2008, Huttunen et al. 2011b, Uusitalo-Seppala et al. 2012). Other examples of 
these biomarkers are pro-adrenomedullin, pentraxin-3, presepsin, CD-64, 
interleukin-6, bactericidal/permeability-increasing protein, phospholipase A2 group 
IIA, and cell-free DNA. 
2.3 Cell-free DNA 
2.3.1 Overview of cell-free DNA 
Cell-free DNA (cfDNA) consists of short-lived fragments of DNA that are released 
because of apoptosis and cell necrosis (Sandquist and Wong 2014). It can be detected 
in plasma, urine, sputum, saliva, stool, and cerebrospinal fluid (Weerakoon and 
McManus 2016). Apart from cellular death, it can be of bacterial origin and it is also 
released from activated host cells such as macrophages and neutrophils (Bhagirath 
et al. 2015). Neutrophils release cfDNA in structures known as neutrophil 
extracellular traps (NETs) (Fuchs et al. 2010, Engelmann and Massberg 2013, Liaw 
et al. 2016). The half-life of cfDNA in blood is ca. 16 min (Lo et al. 1999). 
Cell necrosis is not sepsis-specific and hence there are numerous conditions and 
diseases that have been shown to increase the total circulating cfDNA. They include 
pregnancy, stroke, myocardial infarction, trauma and cancer (Lo et al. 2000, Lau et 
al. 2002, Wu et al. 2002, Chang et al. 2003, Rainer et al. 2003). A prognostic value 
has been shown in acute stroke and acute myocardial infarction (Chang et al. 2003, 
Rainer et al. 2003).  
 29 
A very low level of cfDNA (ca. 0.02 μg/ml) is present in healthy populations (Wu 
et al. 2002). In recent years, the origins of this cfDNA have been under investigation. 
By studying the methylation patterns, one study concluded that the majority of 
cfDNA in healthy persons originates from white blood cells (55%) and erythrocyte 
progenitors (30%), and to a lesser extent from vascular endothelial cells (10%) and 
hepatocytes (1%) (Moss et al. 2018). Furthermore, the evaluation of mutated DNA 
in circulation can be used to detect, genotype and monitor cancer (Wan et al. 2017), 
and foetal cfDNA in maternal blood is a non-invasive test of foetal chromosomal 
abnormality (Fan et al. 2012). 
2.3.2 The role in coagulation and fibrinolysis 
CfDNA is one of the damage-associated molecular patterns (DAMPs). It has a 
pathogenic role in sepsis as the NET-form of cfDNA activates coagulation (O'Brien 
et al. 2017). Moreover, increased levels of cfDNA in sepsis impair fibrinolysis by 
inhibiting plasmin-mediated fibrin degradation (Gould et al. 2015). In summary, 
cfDNA acts as a link between innate immunity and coagulation. Expectedly, cfDNA 
has been shown to be elevated in patients with deep vein thrombosis (Fuchs et al. 
2012). Evidence has also accumulated that cfDNA is a major factor in the 
pathogenesis of disseminated intravascular coagulation (DIC), but this has not yet 
been established in clinical studies (Liaw et al. 2016).  
2.3.3 Cell-free DNA in infections 
Plasma cfDNA is elevated in various conditions and therefore the total cfDNA 
cannot be used as a diagnostic tool. Despite this, one prospective study found that, 
with clinical judgement as a golden standard, within febrile patients it would have an 
extremely high AUC of 0.99 to diagnose an infection (Moreira et al. 2010). 
Nevertheless, it has value in prognosis of patients with bacteraemia and severe sepsis 
(Rhodes et al. 2006, Huttunen et al. 2011a, Dwivedi et al. 2012, Avriel et al. 2014, 
Forsblom et al. 2014, Garnacho-Montero et al. 2014). In these studies, non-survivors 
have had statistically significantly higher values compared to survivors. In patients 
with severe sepsis, AUC in prediction of ICU mortality has been as high as 0.97 
(Dwivedi et al. 2012). In predicting prognosis, it has been reported to be better than 
APACHE II score and biomarkers such as PCT and IL-6 (Dwivedi et al. 2012, Avriel 
et al. 2014).  
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In recent years, the origin of cfDNA in sepsis has been under investigation (Moss 
et al. 2018). In fourteen sepsis patients, the majority of cfDNA originated from 
granulocytes, but if the patient had an elevation of alanine aminotransferase, 
biomarker of hepatocyte damage, more than half of the origin of cfDNA was from 
hepatocytes (Moss et al. 2018). In another study, the identification of circulating 
microbial cfDNA with next-generation sequencing test yielded a 94% agreement 
with blood-culture (Blauwkamp et al. 2019). 
2.4 PCSK9 
2.4.1 Overview of PCSK9 and the role in cholesterol clearance 
The proprotein convertase subtilisin/kexin enzyme 9 (PCSK9) is a liver-produced 
enzyme that binds to the low density lipoprotein receptor (LDL-R) on the surface 
of hepatocytes (Seidah and Prat 2012, Seidah et al. 2018). Binding to the receptor 
leads to the degradation of the LDL-R and higher plasma LDL-cholesterol levels. 
Patients with a PCSK9 loss-of-function (LOF) mutation of the PCSK9 gene have a 
reduced cholesterol level (Cohen et al. 2006, Benn et al. 2010), and the same vice 
versa, patients with the gain-of-function (GOF) mutations have an increased level 
of cholesterol (Leren 2004). If the binding to the receptor is inhibited with 
antibodies, plasma cholesterol level is reduced (Robinson et al. 2015, Sabatine et al. 
2017). Alirocumab and evolocumab are the first antibodies that are in clinical use to 
lower the cholesterol level, especially among patients with familial 
hypercholesterolemia. The results of a meta-analysis on the effects of the antibodies 
show that they reduce both cardiovascular mortality and all-cause mortality 
(Navarese et al. 2015). 
Meta-analysis of 15 cholesterol studies concluded that the normal level of plasma 
PCKS9 in healthy subjects is ca. 200 ng/ml (95% confidence interval (CI) 170-220) 
(Boyd et al. 2016). There is a correlation between plasma PSCK9 level and LDL-
cholesterol level, and the level of PCSK9 is increased in those who use statins. 
(Nozue 2017).  
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2.4.2 PCSK9 in bacteraemia and sepsis 
Low level of LDL-cholesterol has been associated with mortality is sepsis (Wilson et 
al. 2003, Chiarla et al. 2004, Vermont et al. 2005). A study published in 2014 by a 
Canadian group was the first to show that the same receptor that binds to LDL-
cholesterol also binds to lipopolysaccharides (LPSs, endotoxins of Gram-positive 
bacteria) (Walley et al. 2014). Later on, another study concluded that also the uptake 
of Gram-positive lipoteichoic acid (LTA) occurs through LDL-R (Grin et al. 2018). 
Therefore, PCSK9 blockade should clear these pathogenic lipids as the blockade 
prevents the LDL-R from degrading. This new therapeutic strategy has not yet been 
proven in clinical trials, but investigators are starting to recruit septic patients into 
two randomised controlled trials with both alirocumab and evolocumab 
(NCT03634293 and NCT03869073, respectively). 
There are studies that support this strategy. In the 2014 study LOF genetic 
variants were associated with improved survival in septic shock (Walley et al. 2014). 
In another study by the same Canadian group, the presence of multiple (but not 
single) PCSK9 LOF alleles decreased the risk of 1-year death in sepsis survivors 
(Genga et al. 2018). A third study by the same group concluded that the level of 
PCSK9 enzyme would be increased in patients with sepsis (Boyd et al. 2016). In this 
study, the level among septic patients would be higher in those that have 
cardiovascular or respiratory failure and lower in those without any organ failure. 
Statistical analysis on mortality could not be made in their study as only ten of their 
patients died by day 28. Lastly, a murine model by another group has also supported 
this theory (Dwivedi et al. 2016). 
This theory of the beneficial effect of the blockade on bacterial infections has had 
setbacks. In cholesterol studies, there has been no beneficial effect on infections, 
although infections have probably not been under special surveillance. On the 
contrary, some elevation of the incidence of upper respiratory tract infections was 
seen in the alirocumab study (Robinson et al. 2015, Khademi et al. 2018). In the 2014 
work, PCSK9-blocking antibody significantly increased survival of septic mice 
(Walley et al. 2014), but in a later work with mice, the inhibition of PCSK9 did not 
have the same effect on LPS-induced mortality (Berger et al. 2017). Furthermore, in 
a cohort study done with black people living in the United States, analysis of loss-
of-function PCSK9 genetic variants revealed that they were not in increased risk of 
hospitalization for a serious infection (Mitchell et al. 2019). 
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3 AIMS OF THE STUDY 
The aims of this study were: 
 
 
1. To study the characteristics and outcome of blood-culture positive infections 
 
2. To study the importance of the underlying diseases in deaths associated with 
bacteraemia and the role of the underlying diseases in relation to day 7, day 
28, and day 90 deaths 
 
3. To assess the level of cfDNA in bacteraemic patients, and to determine the 
role of plasma cfDNA in predicting prognosis in bacteraemia  
 
4. To assess the level of PCSK9 in bacteraemic patients and to determine the 
level in patients with severe disease or in relation to day 7, day 28, and day 90 
deaths 
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4 MATERIALS AND METHODS 
4.1 The setting 
Tampere University Hospital (TAUH) is the tertiary hospital of the Pirkanmaa 
County with a catchment population of 524 700. At the time of patient collection, 
the hospital ED divided the patients into basic and specialised emergency care 
patients. In specialised care, the vast majority of the patients were internal medicine 
and surgical patients. The hospital has a 24-bed ICU and four different HDUs 
(pulmonary, surgical, cardiology, and internal medicine), all taking care of patients 
with infection. 
4.2 Patients 
4.2.1 The selection of the cases 
The study cohort was gathered prospectively. In the ED, blood cultures are taken 
routinely from patients with suspected infection. The population of the study 
comprises all the blood culture-positive adult patients that were treated in the 
hospital ED specialised care between March 1, 2012 and February 28, 2014. The 
culture-positive cases that were considered as contaminants were excluded. These 
included cases with coagulase-negative Staphylococcus, Bacillus, Micrococcus, 
Cutibacterium, and Corynebacterium without clinical relevance and with detection 
in a single blood culture bottle. Due to technical reasons, some of the culture-
positive cases were missed. These included cases where the culture became positive 
later than 72 hours after the admission to the ED. At that point the blood sample of 
the admission day needed for the biomarker analysis was missed. 
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4.2.2 Clinical data 
The clinical data such as underlying diseases, medication, and clinical parameters at 
the time of the arrival to the ED was gathered from the medical records (paper and 
digital) by the principal investigator. (Data collection form added as an appendix.) 
The site of infection and the main underlying disease associated with death were 
decided by the investigator based on medical records and autopsy records, if 
available. Diagnoses of sepsis, severe sepsis and septic shock were defined according 
to Sepsis-2 criteria (Levy et al. 2003). The definition of sepsis changed at the time of 
the writing of Study I. Hence the naming of the patient cohort changed from sepsis 
patients to bacteraemia patients in Studies II and III. The definition of quick 
Sequential Organ Failure Assessment (qSOFA) was made according to Sepsis-3 
criteria (Seymour et al. 2016) in cases where the necessary data was available. The 
qSOFA score was positive if at least two of the following criteria were fulfilled: 
respiratory rate ≥22/min, systolic blood pressure ≤100 mmHg or the verbal section 
of the Glasgow Coma Scale was altered. The Pitt Bacteraemia Score was calculated 
as presented in the original study (Korvick et al. 1991). Bacteraemia was estimated 
to be healthcare-associated if the symptoms started more than 48 h after admission 
to a healthcare institution, or the bacteraemia was related to a surgical operation in 
the preceding 30 days. 
4.2.3 The categorization of the cause of death 
All patients that died before day 90 were categorized into three different groups 
based on their cause of death. If the death of the patient was bacteraemia-related and 
the patient had a life expectancy of more than six months, the patient was 
categorized into Group 1. If the death was bacteraemia-related, but the life 
expectancy was less than six months, the patient belonged to Group 2. If the death 
was unrelated to bacteraemia, the patient belonged to Group 3. The term 
bacteraemia-related refers to culture-positive cases where the immediate cause of 
death was the bacteraemia, or the bacteraemia was a factor in the chain of events 
leading to death. This categorization was done by two infectious diseases clinicians 
independently using medical records and autopsy records, if available. If the 
categorization differed between the two, a meeting was held together with a third 
clinician and the final decision was made. This categorization was based on the 
severity of the patient’s underlying disease(s), the patient’s pre-performance, severity 
of the bacteraemia, and recovery after the bacteraemia. This categorization was 
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developed by the authors of Study I by partly combining the McCabe classification 
(McCabe and Jackson 1962) and the classification commonly used in death 
certificates (immediate cause of death and underlying cause of death). 
4.3 Microbiological methods and blood sample collection 
Blood cultures were collected in BacT/Alert Aerobic (FA Plus) and Anaerobic (FN 
Plus) blood culture bottles. These bottles were placed in the automated microbial 
detection system BacT/Alert 3D (bioMérieux, France). When a blood culture that 
fulfilled the above-mentioned criteria turned out positive, the clinical microbiologist 
started to collect the blood samples for study analytes. The blood samples were 
collected from patients alongside treatment-based routine laboratory testing. The day 
0 blood sample was collected mostly within the first hours after the patient was 
admitted to the ED, but samples collected within up to 24 hours were included. The 
plasma was extracted from the leftover blood samples and frozen. 
4.4 Cell-free DNA 
The quantification of plasma cfDNA was done by Qubit dsDNA HS Assay Kit and 
Qubit 2.0 fluorometer (Invitrogen, Carlsbad, CA, USA). The manufacturer's 
instructions were followed at each step. The analysis was done twice, and the final 
result was the average of the two samples. The intraǦassay coefficients of variation 
from control samples were between 3.6% and 5.7%. 
4.5 PCSK9 
Plasma PCSK9 was quantitated from plasma samples using an ELISA assay (R&D 
Systems, cat#DPC900) and the manufacturer's recommended protocol. The 
reproducibility of the ELISA was validated by measuring part of the samples twice. 
The intra-array and between-array variations of the samples were on average 3.5% 
of the defined final concentration. 
There were also control samples from another bacteraemia cohort taken one year 
after surviving a bacteraemia (n=17). The method of the collection of these samples 
is described elsewhere (Huttunen et al. 2010). This control group had a median level 
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of 188 ng/ml (inter quartile range (IQR) 139-264) which is in line with the normal 
human range presented in a meta-analysis of non-septic patients (170-220 ng/ml) 
(Boyd et al. 2016). 
4.6 Statistical methods 
The IBM SPSS version 22.0 software (IBM Corp., Armonk, NY, USA) was used for 
most of the statistical analysis excluding some of the analysis in Study III that were 
done with R (version 3.4., www.r-project.org). Nonparametric data were analysed 
with Mann-Whitney U-test or Kruskal–Wallis test when appropriate. A PǦvalue of 
<0.05 was considered significant. Categorical data were analyzed by Chi-square test. 
AUC/receiver operating characteristic (ROC) statistic was used for the predictive 
performance, and the Youden index was used to select optimal cutǦoff value. A 
logistic regression model was used to study the independent effect of a biomarker 
adjusted to potential confounders. Kaplan–Meier method was used for the 
calculation of the survival curve, and survival differences between groups were 
compared by a logǦrank test. 
4.7 Ethical considerations 
The study was approved by the Ethics Committee of Tampere University Hospital, 
Finland, and the National Supervisory Authority for Welfare and Health. The need 
for informed consent was waived as no additional blood sampling was needed and 
routine patient care was not modified. 
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5 RESULTS 
5.1 Characteristics of the study patients (Study I and some 
additional data) 
5.1.1 The final cohort 
During the study period, there were 800 positive blood cultures in patients over 16 
years of age (Figure 1). Contaminants (136) were excluded and 167 were excluded 
for technical reasons. Eleven patients had bacteraemia twice on different admissions 
and one patient had bacteraemia three times. Thus, 497 cases of positive blood 
culture among 484 patients were included in Study I. One box containing 16 samples 
went later missing, hence the total number of 481 cases in Studies II and III. The 
final number of the plasma samples were: day 0: 481, day 1: 446, day 2: 389, day 3: 
300, day 4: 137. The declination of the plasma samples was caused by various 
reasons, for example the patient was discharged, the patient died, or routine 
laboratory tests were not taken on that day.  
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Figure 1.  Patient inclusion in studies I-III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
800 consecutive culture-
positive cases 
167 cases missed 
96 patients with too late 
positive culture 
71 patients missed for 
other reason 
136 cases excluded 
(contaminations) 
497 cases (Study I) 
11 patients with two 
bacteraemia 
1 patient with three 
bacteraemia 
=484 patients 
481 cases (Study II and 
III) 
10 patients with two 
bacteraemia 
1 patient with three 
bacteraemia 
=469 patients 
16 missing samples 
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5.1.2 Characteristics 
Demographic data, chronic medical conditions and previous medications are 
presented in Table 2. Of the total study population, median age was 68 years and 
53% were male. Majority of the culture-positive cases had some chronic disease, only 
11% did not have any chronic medical condition. Furthermore, 19% of cases were 
on oral corticosteroids.  
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Table 2.  Characteristics of the 497 cases with bacteraemia admitted to the Emergency 
Department 
Characteristics Data 
Demographic  
Cases/Patients 497/484 
Men, n (% of cases) 262 (53) 
Women, n (% of cases) 235 (47) 
Median age, y (range) 68 (16-95) 
Chronic medical condition n (% of cases) 
Heart disease 176 (35) 
Diabetes mellitus (any type) 139 (28) 
Neurological disease 112 (23) 
Pulmonary disease 100 (20) 
Kidney disease 68 (14) 
Rheumatological disease 52 (11) 
Alcohol abuse1 52 (11) 
Substance abuse2 10 (2) 
Solid tumor with metastasis 57 (12) 
Haematological malignancy 45 (9) 
MRSA carrier 16 (3) 
ESBL carrier 13 (3) 
Any of the above 426 (86) 
Previous medication n (%) 
Oral corticosteroids 94 (19) 
Antibiotic treatment on admission 58 (12) 
Cancer chemotherapy 56 (11) 
Disease-modifying antirheumatic drugs 21 (4) 
Biological therapy 10 (2) 
Antirejection medication 8 (2) 
                                                   
1 Social or medical problems of alcohol abuse in the past 12 months 
2 Social or medical problems of substance abuse in the past 12 months 
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5.1.3 Causative organisms of blood culture positivity 
Table 3 shows the causative organisms of blood culture positivity. Gram-positive 
and Gram-negative cases were equally common. MRSA and ESBL cases were rare. 
There were no ESBL-Klebsiella cases and only one Candida species. Patients who had 
a polymicrobial infection were mostly gastro-surgical cases. 
Table 3.  Blood culture findings (n=497) 
Organisms n (%) 
Gram positive  225 (45) 
Staphylococcus aureus 74 (15) 
MRSA 3 (1) 
Coagulase-negative Staph. 11 (2) 
Streptococcus pneumonia 52 (11) 
β-hemolytic streptococci 45 (9) 
Viridans streptococci 21 (4) 
Enterococci 17 (3) 
Other gram positive 5 (1) 
Gram negative  223 (45) 
E. coli 159 (32) 
ESBL-E.coli 9 (2) 
Klebsiella sp. 21 (4) 
Pseudomonas aeruginosa 18 (4) 
Other gram negative 25 (5) 
Others 49 (10) 
Anaerobes 15 (3) 
Fungi 1 (0.2) 
Polymicrobial 33 (7) 
5.1.4 Site of infection and initial treatment 
As presented in Table 4, the most common focus was the urinary tract (26%). The 
bacteraemia was associated with healthcare in 81 culture-positive cases (16%). 
Median time from admission to ED to the start of the antibiotic was 174 min (range 
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from -283 min to 1269 min, data available in 446 cases). The range started from 
negative minutes as in some cases the antibiotic was started already at the referral 
site. The median time was 83 minutes in cases that were transferred to ICU. Empiric 
antibiotic was 2nd generation cephalosporin in 57% of the cases. Nineteen cases (4%) 
were treated with sepsis corticosteroids and an additional 6% got corticosteroids due 
to some other indication or the previous corticosteroid dose was adjusted due to the 
infection.   
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Table 4.  Site of infection and the choice of antimicrobial (n=497) 
Variable n (%) 
Site of infection3  
Unknown 118 (22) 
Urinary tract infection 138 (26) 
Intra-abdominal 84 (16) 
Skin, soft tissue and bones 72 (14) 
Lower respiratory tract 54 (10) 
Surgical site or foreign body 36 (7) 
Others 24 (5) 
Antibiotic started on the day of admission  
None 36 (7) 
Monotherapy 385 (77) 
2nd generation cephalosporin 241 (48) 
3rd generation cephalosporin 60 (12) 
Betalactam and betalactamase-inhibitor combination 34 (7) 
Fluoroquinolone 20 (4) 
Carbapenem 11 (2) 
Other betalactam 9 (2) 
Other 10 (2) 
Combination therapy 76 (15) 
Betalactam and fluoroquinolone 30 (6) 
Betalactam and metronidazole 30 (6) 
Other combination 16 (3) 
5.1.5 Severity of bacteraemia 
The clear majority of the culture-positive cases (76%) were treated in general wards 
and 10% of the cases were transferred to ICU. Furthermore, 76% of the cases that 
were qSOFA positive were treated in general wards. Forty-four patients (9%) died 
                                                   
329 cases with two different foci 
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by day 7, 70 (14%) by day 28, 98 (20%) by day 90, and 143 (30%) within one year. 
Table 5 shows the severity of the bacteraemia, essential laboratory values and the 
unit were the case was transferred from ED. All cases had sepsis according to the 
Sepsis-2 definition. The definition of severe sepsis is different from the definition of 
positive qSOFA. Nevertheless, in the material 62% of the cases fulfilled both of the 
definitions, 22% fulfilled neither of them and in 16% there was a discrepancy 
between the definitions (data for the gathering of qSOFA was available on 473 
cases). High (≥4) points in Pitt Bacteraemia Score (PBS) was predictive of death. In 
this study, 39% of patients with high points died by day 7 compared to 26% with 
positive qSOFA. However, the sensitivity of high PBS points was poor as 47% of 
deaths by day 7 were missed. The results regarding the predictive value of qSOFA 
are elaborated in Chapter 5.3.  
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Table 5.  Severity of the bacteraemia, laboratory values, and the unit where the patient was 
transferred from the ED (n=497) 
Variable n (%) 
Severity of the bacteraemia  
qSOFA score ≥24 136 (29) 
Severe sepsis (≥1 organ failure) 152 (31) 
Septic shock 37 (7) 
Need of vasopressor 51 (10) 
Need of mechanical ventilation 26 (5) 
Pitt Bacteraemia Score ≥45 61 (12) 
Laboratory values  
Median day 0 CRP, mg/l (IQR)6 113 (46-218) 
Median day 0 leucocyte count, 109/l (IQR)7 11.7 (7.9-15.8) 
Thrombocytes lower than 100 x109/l on days 0-4, n (%) 122 (25) 
Case was transferred from ED to  
Intensive care unit 48 (10) 
High dependency unit 52 (11) 
Other wards 375 (76) 
Home8 16 (3) 
Patient died in the ED 6 (1) 
                                                   
4 Data available on 473 cases 
5 Data available on 490 cases 
6 Data available on 494 cases 
7 Data available on 494 cases 
8All called the following days, and all but one came back to the hospital. No health deteriorations even though patients were 
discharged on day 0. 
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5.2 The role of the underlying diseases in deaths after the 
bacteraemia (Study I) 
5.2.1 The categorization of the cause of death 
As detailed in the methods, 98 patients who died by day 90 after the bacteraemia 
were categorised into three different groups. Sixteen patients (16%) did not have any 
rapidly fatal underlying disease and the death was bacteraemia-related (Group 1). For 
45 patients, the death was related to the bacteraemia in that it weakened the patient 
leading to the death, which was in any case expected as the patient had a life 
expectancy of less than 6 months (Group 2). For 37 patients, death was not related 
to the bacteraemia as the immediate cause of death was not the bacteraemia nor was 
the bacteraemia a factor in the chain of events leading to death (Group 3). The 
median age in Groups 1, 2 and 3 were 77, 78 and 70, respectively. Of those cases 
that were transferred to ICU (n=48), 21 patients died by day 90. Of these 
succumbed, 11 patients belonged to Group 1. 
5.2.2 The day of death in Groups 1, 2 and 3 
As illustrated in Figure 2, the vast majority of the deaths in Groups 1 and 2 (the 
deaths related to the bacteraemia) happened before day 28 after admittance to the 
ED. Only three patients (3%) in these groups died on days 29 to 90. Furthermore, 
all but one patient in Group 1 died within 7 days after admittance to the ED. 
Nevertheless, the deaths of Group 1 were still a minority of all the deaths by day 7 
as 66% of these deaths belonged to Group 2 and 3. 
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Figure 2.  Number of patients (n=98) in Groups 1, 2 and 3 in relation to the day of death 
 
5.2.3 Detailed analysis of patients in Group 1 (additional data) 
Sixteen patients were categorised to Group 1. The life expectancy of these patients 
was evaluated as being more than 6 months without the bacteraemia. Nevertheless, 
only one patient in this group did not have any underlying disease. Compared to 
Groups 2 and 3, patients in Group 1 had more frequently both positive qSOFA 
(81%) and septic shock (56%) and they were the most frequently transferred to ICU 
(69%). The description of the course of events is detailed in Table 6. 
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Table 6.  The description of the 16 patients whose death was bacteraemia-related and who had 
a life expectancy of more than 6 months 
Age and gender Day of 
death 
Microbe Underlying diseases and description on the course of events 
51, M 7 Capnocytophaga 
canimorsus 
Alcoholism. Sepsis after a dog bite. 6 days in ICU because of DIC, 
renal failure, seizure, and hypotension. Transferred to normal ward, 
found dead the first night. Forensic autopsy records not available. 
55, M 0 E. coli Alcoholism, liver fibrosis, schizophrenia. Found lying in bed with low 
GCS points. MODS diagnosed, dies in ICU the same day. 
55, M 0 Str. pneumoniae Alcoholism, liver fibrosis, neurocognitive impairment, renal disease. 
Found lying in bed with low GCS points. Diagnosed in ED with 
pneumonia and sepsis, dies in ICU the same day. 
60, M 0 Staph. aureus Alcoholism. Cortisone started to symptoms resembling polymyalgia 
rheumatica. Then vomiting, feeling ill and arrived to ED with renal 
failure, condition deteriorated and MODS diagnosed, died in ICU the 
next day. 
63, F 39 Str. pneumoniae Coeliac disease. 39 days in ICU because of persistent MODS and 
multiple amputations due to severe DIC. Died in ICU.  
73, F 0 E. coli DM2, mentally retarded. Arrived with a difficult dyspnoea and dies 
in ED. Autopsy revealed severe pulmonary embolism and 
pyelonephritis. Embolism categorized being secondary to infection. 
74, F 0 Bacteroides uniformis DM2. Carcinoma of the sigmoid and metastasis in regional lymph 
nodes operated half a year before. Died in operation room due to 
peritonitis caused by adhesive occlusion of intestine. 
76, M 0 E. coli DM2, nephropathy, metabolic syndrome and colostomy due to 
operated tubular adenoma of colon years ago. Arrived to ED 
because of abdominal pain, diagnosed with intestinal perforation, 
condition deteriorates in operation room, operation ceased and dies 
shortly after.  
78, M 0 E. coli DM2, heart failure, Alzheimer. Arrived to ED with abdominal pain, 
diagnosed with perforation of the sigma. Operated, but dies because 
of renal and cardiac failure in ICU. 
78, F 3 Staph. aureus No underlying diseases. Pain in neck for a week, no fever. Seeks 
help from acute primary care. Condition deteriorates and gets 
cardiac arrest. Resuscitated, return of spontaneous circulation in 24 
minutes. Transferred through ED to ICU. Diagnosed with anoxic 
brain damage and dies in ICU. Forensic autopsy records not 
available. 
79, M 0 E. coli Chronic obstructive pulmonary disease, aortic stenosis and 
regurgitation. Arrived to regional hospital because of pelvic pain. 
Diagnosed with urethral stone. Condition deteriorates and 
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transferred through ED to ICU. Diagnosed with urosepsis and 
MODS. Restrained from mechanical ventilation and dialysis due to 
prior low pulmonary capacity and dies in ICU the same day. 
80, M 0 Klebsiella oxytoca, E. 
coli 
Asthma. Arrives to ED with hypotension and MODS. Dies in ED. 
Clinical suspicion in ED and autopsy records conclude that patient 
died to cholecystitis and sepsis. 
82, F 0 Klebsiella pneumoniae DM2, previous stroke. Diagnosed in ED with both sepsis and a new 
cerebral infarct. Dies in ICU. K. pneumoniae was cultured also in 
urine.  
87, F 2 Str. pneumoniae Asthma, coronary disease. Found lying in home, diagnosed with a 
cerebral infarct in ED, dies feverish and unconscious in stroke unit. 
Infarct categorized being secondary to infection. 
93, F 4 Enterobacter 
aerogenes 
Arteriosclerosis obliterans, renal disease. First episode of infection 
a month before, gets Clostridium difficile –diarrhoea, arrives to ED 
with low GCS-points, diagnosed with urosepsis, dies in a normal 
ward. 
94, F 1 H. influenzae Asthma, coronary disease, pulmonary embolism. Arrives with 
dyspnoea to ED, dies in high dependency unit to pneumonia and 
renal failure. 
DIC = Disseminated Intravascular Coagulation, DM2 = Diabetes Mellitus type2, ED = Emergency Department, F= Female,  
GCS = Glasgow Coma Scale, ICU = Intensive Care Unit, M = Male, MODS = Multiple Organ Dysfunction Syndrome 
5.2.4 The main underlying disease associated with death of patients in 
Groups 2 and 3 
Table 7 presents the main underlying disease of the 79 patients in Groups 2 and 3. 
With 30 patients, solid tumour with metastasis was the most common underlying 
disease associated with death and haematological malignancy was the second 
common with 10 patients. Thus, malignancies combined were associated with 41% 
of all deaths in bacteraemia.   
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Table 7.  The main underlying disease associated with the death of the 79 patients in Groups 2 
and 3 
Underlying disease n (%) 
Solid tumour with metastasis 30 (38) 
Haematological malignancy 10 (13) 
Liver disease 10 (13) 
Neurological or neurosurgical disease 7 (9) 
Heart disease 6 (8) 
Diabetes mellitus (any type) 4 (5) 
Renal disease 2 (3) 
Other 3 (4) 
No data / not classifiable 7 (9) 
5.3 Cell-free DNA (Study II) 
5.3.1 Level of plasma cfDNA on days 0 to 4 after admission to the ED 
The day 0 plasma cfDNA was analysed from 481 culture-positive cases (469 
patients). The median level on day 0 was 1.38 μg/ml (range 0.75 to 38.85). As detailed 
in Table 8, the median level was higher on the day of admittance in those who died 
by day 7 compared to those who survived. Survivors had statistically significantly 
lower median levels on days 1 to 4 as well.   
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Table 8.  Plasma cfDNA levels on day 0 to 4 after admission to ED in all cases and in relation to 
death by day 7 
 Plasma cfDNA (μg/ml), median (quartiles)  
Days after admission All (n=481) Non-survivors (n=44) Survivors (n=437) P-value 
Day 0 1.38 (1.20-1.77) 2.02 (1.51-2.92) 1.35 (1.19-1.66) <0.001 
Day 19 1.36 (1.18-1.73) 2.20 (1.57-3.63) 1.33 (1.17-1.64) <0.001 
Day 210 1.35 (1.16-1.65) 1.87 (1.59-2.92) 1.33 (1.16-1.61) <0.001 
Day 311 1.33 (1.16-1.61) 1.81 (1.48-4.34) 1.32 (1.14-1.58) <0.001 
Day 412 1.35 (1.17-1.71) 1.66 (1.49-2.38) 1.33 (1.15-1.68) 0.017 
Maximum value 1.49 (1.28-1.91) 2.24 (1.56-4.55) 1.45 (1.27-1.81) <0.001 
5.3.2 Factors affecting the level of cfDNA 
The factors affecting the level of cfDNA on the day of admission were analysed 
(Table 9). The following factors did not have a statistically significant effect on the 
level and they were excluded from the table: cardiovascular disease, diabetes, chronic 
kidney disease, solid tumour with metastasis, Gram-positive bacteraemia, and 
polymicrobial infection. Patients with haematological malignancy had a level that was 
statistically significantly lower than in cases without such malignancy (median 1.27 
μg/ml, IQR 1.12-1.68, p=0.041). The level of cfDNA was higher in cases with a 
positive marker on the severity of the infection.  
                                                   
9 Data available on 446 cases 
10 Data available on 389 cases 
11 Data available on 300 cases 
12 Data available on 137 cases 
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Table 9.  The characteristics and underlying conditions that had a statistically significant effect 
on the level of cfDNA on the day of admission  
 Plasma cfDNA (μg/ml) on day of admission to the 
emergency department 
 
 factor present, median 
(quartiles) 
factor absent, median 
(quartiles) 
P-value 
Characteristics and underlying 
conditions 
   
Male 1.42 (1.24-1.85) 1.30 (1.16-1.64) 0.002 
Age over 60 years 1.39 (1.22-1.80) 1.32 (1.16-1.60) 0.035 
Age over 80 years 1.46 (1.25-1.89) 1.35 (1.18-1.69) 0.020 
Liver disease 1.91 (1.41-2.15) 1.35 (1.19-1.67) <0.001 
Alcohol abuse13 1.95 (1.47-2.38) 1.34 (1.18-1.64) <0.001 
Severity of the infection    
qSOFA score ≥214 1.56 (1.26-2.20) 1.34 (1.16-1.64) <0.001 
Severe sepsis 1.61 (1.31-2.23) 1.31 (1.17-1.60) <0.001 
Septic shock 1.96 (1.32-2.83) 1.36 (1.19-1.70) <0.001 
Admitted from ED to ICU 1.95 (1.40-2.89) 1.35 (1.19-1.69) <0.001 
Pitt Bacteraemia Score ≥415 1.83 (1.34-2.73) 1.35 (1.19-1.68) <0.001 
5.3.3 The prognostic value of cfDNA in comparison to qSOFA 
As presented in Table 8, patients that died by day 7 had significantly higher levels of 
cfDNA compared to those that survived. CfDNA had an AUC of 0.77 (95% CI 0.69 
to 0.85) in predicting death by day 7. QSOFA having AUC 0.77 (95% CI 0.70 to 
0.85) was comparable with cfDNA. The cut-off value of cfDNA was estimated using 
ROC curve (Figure 3). The prognostic values of both the cut-off value of 1.69 μg/ml 
and positive qSOFA are shown in Table 10. In cases that had both positive qSOFA 
and cfDNA ≥1.69 μg/ml, the specificity in prediction of death rose to 93%, but the 
sensitivity declined to 61% (AUC 0.77). This high specificity can be seen in the 
Kaplan-Meier survival curve presented in Figure 4. Combination of positive qSOFA 
and cfDNA >1.69 μg/ml resulted in a 20-fold risk of death by day 7 compared to 
those with negative qSOFA and cfDNA <1.69 μg/ml. 
                                                   
13 Social or medical problems of alcohol abuse in the past 12 months 
14 Data available on 458 cases 
15 Data available on 474 cases 
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Statistically significant variables associated with death by day 7 were liver disease, 
alcohol abuse, cardiovascular disease, Pitt Bacteraemia Score ≥4, cfDNA level ≥1.69 
μg/ml and positive qSOFA score. In a multivariable analysis on these factors, liver 
disease and alcohol abuse did not remain significant; other factors remained. 
Contrary to cfDNA, C-reactive protein (CRP) on day 0 did not have a significant 
predictive value for death by day 7 (AUC 0.52, 95% CI 0.43 to 0.60, data on 478 
cases).  
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Figure 3. Receiver operating characteristic (ROC) curve on day 0 level of cfDNA, qSOFA score ≥2, 
and level of CRP in relation to death by day 7. 
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5.3.4 The level of cfDNA in the three death categories (additional data) 
The level of day 0 cfDNA was calculated in the three different categories used in 
Study I. Among patients who died by day 90, the level was the highest in Group 1 
with a median of 2.78 μg/ml (IQR 1.87 to 4.93) and the lowest in Group 3 (median 
1.79 μg/ml, IQR 1.43-2.36). The median level was the lowest in survivors. The levels 
of groups with 95% CI are presented in Figure 5. The difference between the groups 
is statistically significant (p<0.001). 
Figure 5.  Median cfDNA levels on day 0 with 95% confidence intervals in the three death categories 
and in patients that survived more than 90 days 
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5.3.5 Patients with the highest level of cfDNA 
Thrombocyte level was lower than 100 x109/l in 116 cases. These cases had 
statistically significantly higher level of day 0 cfDNA than cases with level over 100 
x109/l (median 1.72 μg/ml vs. median 1.33 μg/ml, p<0.001). Other DIC parameters 
including fibrinogen, thromboplastin time and D-dimer were not routinely 
investigated in all study patients. Nevertheless, DIC resulting in amputations was 
present in three of the top five cases with the highest level of cfDNA on day of 
admission. The patient with the highest level of cfDNA (38.85 μg/ml) had a serious 
pneumococcal infection resulting in multiple amputations. Two other patients in the 
top five cases had infections caused by Capnocytophaga canimorsus with levels of 9.65 
μg/ml and 8.92 μg/ml. Their infections also resulted in skin necrosis and 
amputations. The third and the last patient with bacteraemia caused by Capnocytophaga 
canimorsus also had a high level of cfDNA that was twice the median and in the top 
five percent of cases (3.05 μg/ml, median 1.38 μg/ml). 
5.4 PCSK9 (Study III) 
5.4.1 PCSK9 levels on days 0-4 after admittance to ED, and levels 
stratified by different factors 
The level of PCSK9 was elevated in bacteraemic patients. The median PCSK9 level 
on day 0 was 376 ng/ml (IQR 293-483), which is statistically significantly higher 
compared to the small group of control patients (median 188 ng/ml, IQR 139-264, 
p=0.001). The concentration of PCSK9 stayed on a high level on days 1 to 4 as well, 
with medians of 383, 381, 360 and 356 ng/ml, respectively. As presented in Table 
11, male cases and cases with liver disease and alcohol abuse had a statistically 
significantly lower level of day 0 PCSK9. Cases that used statins had a significantly 
higher level.   
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Table 11.  The level of PCSK9 stratified by different characteristics and underlying conditions 
(n=481) 
  Plasma PCSK9 level (ng/ml) on day of admission  
Characteristics and underlying 
conditions 
n (%) factor present, median 
(quartiles) 
factor absent, median 
(quartiles) 
P-value 
Male 253 (53) 356 (273-472) 405 (310-492) 0.001 
Age over 60 years 333 (69) 381 (298-486) 368 (275-478) 0.223 
Age over 80 years 107 (22) 379 (304-477) 376 (289-485) 0.804 
Cardiovascular disease 155 (32) 388 (299-479) 371 (291-484) 0.868 
Diabetes any type 137 (29) 375 (295-468) 379 (292-487) 0.591 
Chronic kidney disease19 66 (14) 364 (297-440) 379 (292-487) 0.152 
Liver disease 49 (10) 284 (176-352) 389 (305-488) <0.001 
Alcohol abuse20 49 (10) 264 (190-388) 388 (306-489) <0.001 
Solid tumour with metastasis 55 (11) 399 (291-484) 375 (293-482) 0.783 
Haematological malignancy 45 (9) 382 (308-485) 376 (291-484) 0.508 
Use of oral corticosteroids 92 (19) 415 (306-487) 370 (291-480) 0.125 
Use of statins 116 (24) 413 (335-532) 363 (283-468) <0.001 
5.4.2 The level of PCSK9 in relation to the causative bacteria and site of 
infection 
There was no statistically significant difference in the level of PCSK9 between Gram-
positive or Gram-negative bacteria (median 381 ng/ml vs. 380 ng/ml, respectively, 
p=0.499). Cases that had bacteraemia caused by Streptococcus pneumonia had the 
highest day 0 level (476 ng/ml, IQR 319-561), and cases with a polymicrobial 
infection the lowest (311 ng/ml, IQR 235-501). In accordance with the causative 
microbe, cases whose site of infection was lower respiratory tract had the highest 
level of PCSK9 compared to other foci (472 ng/ml, IQR 315-557). Cases whose site 
of infection could not be classified or was unknown had the lowest level (352 ng/ml, 
IQR 262-474).  
                                                   
19 History of creatinine more than 120 μmol/l 
20 Social or medical problems of alcohol abuse in the past 12 months 
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5.4.3 PCSK9 as an acute phase reactant 
As the level of PCSK9 was higher in this bacteraemia cohort compared to the normal 
human range, Pearson’s product-moment analysis was used to study the possible 
correlation between PCSK9 and other infection-associated markers. There was no 
correlation between day 0 level of PCSK9 and day 0 leukocyte number, body 
temperature, or cfDNA (data not shown), but there was a significant positive 
correlation to CRP on days 0 to 4 (p<0.001 on all days). The day 0 correlation is 
illustrated in Figure 6. In bacteraemia caused by Str. pneumoniae, the level of PCSK9 
and day 0 CRP were the highest of all bacteraemias (PCSK9 median 476 ng/ml, CRP 
median 212 mg/l).  
Figure 6.  The correlation between day 0 plasma level of PCSK9 and day 0 C-reactive protein. The 
shadowed area shows the 95% confidence interval. 
 
5.4.4 The level of PCSK9 in relation to the severity of the bacteraemia and 
death 
As presented in Table 12, PCSK9 level was negatively associated with the severity of 
sepsis. Nevertheless, among these the only statistically significant indicator was the 
need of vasopressors (p=0.026), and there was a strong trend towards significance 
in cases that were transferred to ICU (p=0.05). One indicator was an exception; cases 
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with qSOFA score ≥2 did not have a lower level but the same as cases with the score 
<2. Patients that died by day 7, day 28 and day 90 all had a statistically significantly 
lower level of day 0 PCSK9. The 45 patients that died by day 7 had a median level 
of 306 ng/ml (IQR 257-454), which is still on a higher level than the normal range 
of 170-220 ng/ml. Patients that died by day 28 and day 90 had a median level of 308 
ng/ml and 320 ng/ml, respectively. The exclusion of cases who were using statins 
did not change these results; the patients that died by day 7 and day 28 had a 
significantly lower level of PCSK9 nevertheless. In contrast, if cases with liver disease 
were excluded, the association between low PCKS9 and death by day 7 or day 28 
would be insignificant (p=0.336 and p=0.059).  
Table 12.  Plasma PCSK9 levels on the day of admission to the emergency department in 
relation to the severity of the bacteraemia (n=481). 
  Plasma PCSK9 level(ng/ml) on day of admission 
Severity of the bacteraemia n (%) factor present, median 
(quartiles) 
factor absent, median 
(quartiles) 
P-value 
qSOFA score ≥221 128 (28) 378 (263-489) 376 (299-480) 0.564 
Need of vasopressor 49 (10) 316 (256-438) 379 (298-486) 0.026 
Need of mechanical 
ventilation 
24 (5) 309 (235-593) 377 (395-481) 0.631 
Severe sepsis22 145 (30) 363 (266-477) 380 (301-486) 0.120 
Septic shock4 36 (8) 347 (256-438) 378 (296-486) 0.110 
Admitted from ED to ICU 44 (9) 343 (256-431) 379 (297-486) 0.050 
Pitt Bacteraemia Score ≥423 58 (12) 344 (262-493) 380 (298-482) 0.323 
Death by day 7 45 (9) 306 (257-454) 381 (298-486) 0.022 
Death by day 28 71 (15) 308 (242-431) 387 (299-487) 0.001 
Death by day 90 101 (21) 320 (249-441) 388 (307-489) 0.001 
                                                   
21 Data available on 458 cases 
22 According to Sepsis-2 definition 
23 Data available on 474 cases 
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6 DISCUSSION 
6.1 Characteristics of the study cohort 
The characteristics concerning age, sex, underlying diseases, and source of infection 
are similar to what is reported in the literature (Diekema et al. 2003, Lee et al. 2007, 
Ortega et al. 2007). The all-cause mortality is also similar to other community-onset 
bacteraemia studies (Lee et al. 2007, Ortega et al. 2007). Distribution of pathogens 
in this study is slightly different than reported in nationwide statistics as the latter 
also includes hospital-acquired infections (Jaakola et al. 2018). Nevertheless, two of 
the most common pathogens are the same (E.coli and Staphylococcus aureus).  
Second generation cephalosporin was the most popular choice of antibiotic (57%, 
including combination therapies). This antibiotic is in first-line choices in different 
Finnish guidelines concerning common bacterial foci such as urosepsis and sepsis of 
unknown focus (Rintala and Karlsson 2017, Urinary tract infections: Current Care 
Guidelines 2019), and hence the popularity could be justified. MRSA was rare among 
positive blood-cultures in ED (3 cases) even though at the time of patient gathering 
it was epidemic in Pirkanmaa region (Jokinen et al. 2015). In this study vancomycin 
was started to nine cases; more widespread use of empiric vancomycin is not 
necessary. 
The median time before the start of the antibiotic was 174 minutes after arriving 
to ED. This is a longer time than those reported in sepsis literature (Kumar et al. 
2006, Ferrer et al. 2014, Lee et al. 2017). However, one has to remember that there 
might be publication bias in the reported literature. The median time to the start of 
antibiotics in culture-positive cases that were transferred to ICU was much less (83 
minutes). All the studies that have found that it matters how rapidly the antibiotics 
are started in the ED are retrospective ones that used complex statistical calculations, 
and they still might be biased (Klompas et al. 2018). The only prospective study did 
not find any benefit (Alam et al. 2018). Nevertheless, there should be no delay in 
ED, especially in cases with septic shock (Liu et al. 2017).  
As much as 94 cases (19%) were on oral glucocorticoids upon arrival to the ED. 
The dose was increased in only 16 cases (3%). Additional 15 cases (3%) got 
glucocorticoids due to some other indication, such as asthmatic obstruction, and 19 
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(4%) got hydrocortisone for sepsis. Not all of those who are on oral glucocorticoids 
need a dose adjustment when they have an infection, but in any case, it needs to be 
remembered in many of them (van der Goes et al. 2014).  
6.2 Sepsis mortality 
6.2.1 The new method of categorization and two other methods 
comparable to it 
Even though widely used, the term “sepsis mortality” is vague. Every patient has 
gone through their unique events before death and sepsis can be a major factor in 
this story or only a sideshow. It has been known that underlying diseases have an 
impact on the prognosis of sepsis patients, but the magnitude of this role has been 
studied less. As an example, it has been known that severe sepsis is a common and 
deadly complication in cancer patients (Williams et al. 2004). In the current study, a 
new method was used in which the patients who deceased were categorised into 
three different groups. Bacteraemia played a major role only in the deaths of patients 
in Group 1. In Group 2, the bacteraemia was more of a last hit to patients with a 
poor prognosis, and the bacteraemia had no role in the deaths of Group 3. Group 1 
turned out to be the smallest, only 16% of deaths were bacteraemia-related and the 
patients had a prognosis of more than 6 months. The biggest group (48%) were 
those whose death was still bacteraemia-related, but these patients had a poor 
prognosis anyway. In 36% of deaths, bacteraemia was not the immediate cause of 
death nor a factor in the chain of events leading to death. Among these bacteraemic 
patients, deaths were associated with cancer in particular; ca. 50% of deaths when 
solid and haematological cancers were combined. Other examples of deadly 
underlying diseases were liver disease and neurological disease. 
The method has limitations. The stratification of patients was made by clinicians 
using medical records. Thus, it may be exposed to limited information as well as 
subjective presumptions of the life expectancy. Only one patient that was stratified 
to Group 1 was without any underlying disease, and the patients in this Group 1 
were as aged as the patients in other groups (median age 77). Hence the stratification 
should be done by at least two clinicians to improve validity. The method should 
also be tested in non-bacteraemic sepsis patients before it can be generalized to 
sepsis patients as a whole.  
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An almost similar method has been published recently (Kopczynska et al. 2018). 
The study focused on the attributable fraction of mortality due to sepsis and also 
stratified the patients into three different groups: “Sepsis-related”; “Possibly sepsis-
related” and “Non-sepsis related”. Patients fulfilling the Sepsis-3 criteria both in ED 
and general wards were included. Instead of clinical judgement, the categorization 
was based on a pre-specified algorithm which had criteria such as “Death within 14 
days of sepsis episode” or “Treated with intravenous antibiotics at the time of index 
episode”. Out of 166 deaths, 40 deaths were either sepsis-related or possibly sepsis-
related. They concluded that 7% (12 cases) of these deaths were directly related to 
sepsis, a percentage slightly smaller than the percentage of Group 1 in Study I (16%). 
Of note, 70% of these patients that died had an existing “Do Not Resuscitate” order 
reflecting serious underlying diseases. 
In another recent retrospective cohort study, researchers randomly selected 
patients that either died in the hospital or were sent to hospice (Rhee et al. 2019). 
They also used clinicians to review the immediate and underlying causes of death, 
but also the preventability of the sepsis-associated death using a 6-point Likert scale. 
They found that sepsis was the most common immediate cause of death and the 
three most common underlying causes of death were solid cancer, chronic heart 
disease and hematologic cancer. They concluded that most sepsis-associated deaths 
were unlikely to be preventable through better hospital-based care. There are 
exceptions, but in general the same conclusion could be drawn from Study I. 
6.2.2 The lack of effect on mortality in clinical sepsis trials 
Numerous randomized clinical trials on sepsis treatment have not demonstrated a 
statistically significant difference in the primary end point (i.e. death) (Marshall 2014). 
For this reason it has been suggested that other endpoints, such as organ function 
variables, should be considered instead (Cohen et al. 2015). One explanation for this 
lack of effect is that sepsis medications tangle only some pathophysiological 
phenomenon of sepsis, not the pathophysiology of the underlying diseases. In this 
study, Table 6 presented the healthiest of all bacteraemia patients that died (Group 
1 patients). What can be seen from this table is that, with some exception, even the 
healthiest had plenty of different underlying diseases, and patients sicker than them 
can be helped even less by a new sepsis drug. 
Many of the sepsis trials are conducted in ICUs. There the patient selection is 
different from other wards; patients should be neither too healthy to benefit of ICU, 
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nor too sick. In the current study 10% of the cases were transferred to ICU and 44% 
of these died by day 90. Around half (10 out of 21) of these deceased were 
categorised to Groups 2 and 3. Hence, the underlying diseases have a major role in 
the deaths of bacteraemic ICU patients as well.  
Furthermore, one has to remember that in some of the deaths that were 
categorised as belonging to Group 1, sepsis was not the immediate cause of death, 
only more of an underlying disease. The immediate cause of death was in some cases 
a complication of sepsis, such as stroke or pulmonary embolism that had occurred 
already at home. Moreover, 4 out of the 16 patients in Group 1 died of 
uncontrollable abdominal catastrophe. These are examples of cases in which sepsis 
medication is probably not of help. 
6.2.3 The endpoints of day 7, day 28, day 90 and in-hospital mortality 
What endpoint of time to use in sepsis studies has been under debate (Cohen et al. 
2001, Vincent 2004, Marshall et al. 2005). There are also discussions that mortality 
would not always be the best endpoint, but morbidity and quality of life would 
(Vincent 2004, Marshall et al. 2005). It has been difficult to say at what point death 
is not related to sepsis anymore (Vincent 2004). This study showed that even death 
by day 7 after bacteraemia does not mean that the infection is a major factor in the 
death. In 66% of the deaths by day 7, the major factor in death was the underlying 
disease and the bacteraemia was only the last hit, if not even that. Even more with 
deaths by day 28, 79% of the patients belonged to Groups 2 and 3. Lastly, although 
day 90 mortality is often used as an endpoint in literature, these results show that as 
much as 84% of the deaths by this day are actually something else than deaths 
attributable to the infection. The use of day 90 mortality might be justified in the 
safety issues of new sepsis drugs.  
Moreover, the endpoint of in-hospital mortality is a controversial measure, 
because it may be depending on many factors which are related to hospital policies 
and not to sepsis itself. As examples, the palliative care might be given either in 
hospital or at home, and the naming of the facilities that give geriatric care could be 
either hospital or something else. 
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6.3 CfDNA 
Circulating nucleic acids were discovered already in the 1940s (Mandel and Metais 
1948). In this century, the prognostic value of cfDNA in sepsis, stroke and acute 
myocardial infection has been under investigation. The current study added evidence 
that cfDNA is of use in bacteraemic ED patients, and the prognostic value is 
comparable to qSOFA. For example, adding cfDNA level measurement to all 
patients that have qSOFA score ≥2, a clinician could find patients that are in 
especially high (20-fold) risk of death. Furthermore, the level was the highest in 
Group 1 (death category used in Study I) indicating that the infection in itself was a 
main factor in this elevation, and not that much the underlying diseases. 
There are other biomarkers that have been suggested for prognostic use as well. 
In studies carried out with suPAR, AUC in predicting death by day 28 has been 
around the same than in this study and in other studies with cfDNA (suPAR 0.79-
0.84 vs. cfDNA 0.76-0.84) (Huttunen et al. 2011a, Huttunen et al. 2011b, Uusitalo-
Seppala et al. 2012). These results are somewhat better than results from ICU-studies 
with, for example, secretoneurin, N-terminal pro–B-type natriuretic peptide and 
chromogranin A which have had AUC in predicting hospital mortality of less than 
0.70 (Rosjo et al. 2012, Rosjo et al. 2016).  
Recent studies have revealed that cfDNA and DNAǦbinding proteins appear to 
have a major importance in the pathogenesis of DIC (Liaw et al. 2016). This study 
added some evidence that cfDNA is particularly high in septic patients with DIC 
even though the study could not establish it. Results are indicative that if a patient 
has a particularly high cfDNA on day 0, there is a chance that the patient might end 
up having skin necrosis. All three Capnocytophaga canimorsus patients had multiple 
times the median level of cfDNA and a patient with serious pneumococcal infection 
that ended up in multiple amputations had 20 times the median level. Furthermore, 
it is also not established whether or not the elevation of cfDNA in patients like these 
occurs through active secretion from neutrophils or from necrosis. The study 
investigating the origins of cfDNA in sepsis patients found that it originated from 
neutrophils (Moss et al. 2018), but in this study the number of cases was small and 
the possible presence of DIC is not reported. 
In general, there are four different categories where biomarkers could be of use: 
as a diagnostic tool, as a tool for staging of disease severity, for prediction and 
monitoring of clinical response to an intervention, and as an indicator of prognosis 
(Selleck et al. 2017, Califf 2018). The best biomarkers are of help in all these 
categories. Present study, and studies done earlier (Chang et al. 2003, Rainer et al. 
 67 
2003, Rhodes et al. 2006), have indicated that the (total) level of cfDNA has first and 
foremost value in prognosis, but further studies might indicate that there could be 
use in diagnostics and disease severity as well, particularly concerning DIC. 
6.4 PCSK9 
The bacteraemic patients in this study had approximately twice the level of PCSK9 
compared to the normal human range, and this upregulation of PCSK9 continued 
until day 4. Infections caused by Gram-positive or Gram-negative microbe had the 
same level even though LPS originating from Gram-negative bacteria has been more 
commonly linked to PCSK9. A recent study concluded that also LTA originating 
from Gram-positive bacteria are removed in a LDL-Receptor/PCSK9 dependent 
manner (Grin et al. 2018), but it could also be that the level of PCSK9 is not 
dependent on level of these pathogenic lipids.  
The level of PCSK9 was statistically significantly higher in pneumococcal 
infections and lower respiratory infections compared to other microbes and foci. 
Similarly, the level of CRP was the highest in pneumococcal infections. These results 
are in line with another result of this study that the level of PCSK9 has a significant 
positive correlation to CRP. Another way how PCSK9 resembled CRP was that the 
level was lower in patients with liver disease. Moreover, another study has also 
suggested PCSK9 as an acute phase reactant as they found a positive correlation with 
PCSK9 and TNF-alfa plasma levels in healthy adults (Ricci et al. 2018). 
These results were contrasting with some of the previous PCSK9 studies. A 
Canadian group has presented that the more severe the infection, the higher the level 
of PCSK9 (Boyd et al. 2016). The results of this study were vice versa; those who 
had more severe infection had a lower level of PCSK9. The same Canadian group 
has also presented that patients with PCSK9 loss-of-function genetic variants have 
improved survival after septic shock (Walley et al. 2014), but another group did not 
find any protective effect among patients with these genetic variants (Mitchell et al. 
2019).  
The present study was the first to study mortality and the level of PCSK9 in 
patients with infection. The study found that the level was significantly lower in 
patients that died by day 7 and day 28 compared to those that survived the 
bacteraemia, but still higher than within healthy patients. In other words, reduced 
plasma PCSK9 response was associated with mortality. As presented in the cfDNA 
study, CRP does not behave the same way; there is no specific CRP level indicating 
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increased mortality. The function of CRP is, for example, to activate complement 
(Thompson et al. 1999), but studies on the function of PCSK9 in infections are still 
scarce. 
6.5 Future considerations 
In clinical sepsis trials, some method to get rid of the confounding effect of the 
underlying diseases is needed so that the effect of sepsis itself would stand out (if 
existing). For example, in the only prospective study about the timing of the 
antibiotic (a pre-hospital antibiotic trial), 40% of the patients had a Do Not 
Resuscitate policy on admission (Alam et al. 2018). Researchers could read the 
medical records of the patients that were deceased post-hoc and stratify them in 
groups to find the patients where sepsis was the major factor in death. The results 
of this subgroup are not that generalizable in the same way as results of a trial with 
many exclusion criteria, but just a modification of exclusion criteria does not solve 
the problem. As both the patients and the events before the patients die are unique, 
pre-specified algorithms are not able to stratify patients to different death categories 
as well as clinical judgement. The method of using clinical judgment has limitations, 
but if a post-hoc analysis reveals that the medication (such as antibiotics or activated 
protein C) or policy (such as timing of the antibiotic) has an effect, further studies 
could be initiated. 
If a future trial establishes that all septic patients with DIC have strongly elevated 
level of cfDNA, a clinician might already on day 0 find whom to allocate the effort 
to stop this devastating complication of sepsis. For now, there is no effective 
treatment to stop the necrosis, but it remains to be seen if this treatment could be, 
for example, a drug that stops the active secretion of cfDNA from neutrophils or a 
drug that binds the cfDNA or something else.  
Total cfDNA has been shown to have value in the prognosis of the patients. The 
turnaround time on the laboratory analysis of cfDNA level is approximately 10 min, 
but it first needs plasma extraction which may limit its use as point-of-care test. It 
remains to be seen if it will be taken into clinical practise for example in DIC patients. 
In any case, instead of total cfDNA, there is already one established clinical test that 
uses cfDNA. Testing foetal cfDNA from maternal blood decreases the need of 
amniocentesis in the screening of chromosomal deficiencies (Ehrich et al. 2017). 
This is only one example where the origin of cfDNA could be of clinical use. 
Especially in cancer research, the so called liquid biopsy is a hot topic (Corcoran and 
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Chabner 2018). Cell-free circulating tumour DNA (ctDNA) could be of help in all 
stages of cancer care; in search of a source tissue, in checking the response to 
treatment etc. Similar to cfDNA, non-coding RNAs (especially 
microRNAs/miRNAs) are on the rise to diagnostics as well. Together these are 
called circulating nucleic acids, and the research on them has not stopped at cancer, 
but continued on to for example heart failure. (Reithmair et al. 2017, Huang et al. 
2019). Furthermore, it could be that in the future we might be seeking for a microbial 
cfDNA from our ED patients. A recent study achieved 94% agreement with blood 
culture using a next-generation microbial cfDNA sequencing test (Blauwkamp et al. 
2019). 
The role of both the LDL-receptor and PCSK9 enzyme in clearance of 
pathogenic lipids was only recently discovered. No definitive answer can be given 
on the effect of PSCK9 antibody on septic patients before a randomized controlled 
clinical trial has been performed. They have been safe drugs in cholesterol studies, 
but even this proof of safety cannot be directly transferred into a different 
population; i.e. to septic patients.  
6.6 Strengths and limitations  
The strengths of the study are the relatively high number of cases (497) whose data 
is not gathered from registries but individually and prospectively, and the including 
of only culture-positive cases which are more likely to represent true infections than 
cases with suspected infections that are culture-negative. Another strength is that 
due to the design of the study, cfDNA and PCKS9 levels could be studied already 
on day 0. 
This study also has some limitations. This was a single-centred cohort concerning 
only culture-positive cases. These results should not be straightforwardly 
extrapolated to culture-negative cases with infection. Furthermore, 167 cases were 
missed due to technical reasons. The potential bias on the material was assessed by 
reviewing the bacteraemia that were not included in the study. The percentages of 
the most common bacteraemia (E. coli and Staphylococcus aureus) did not differ between 
the study population and the cases that were missed. Among cases included 
compared to those not included, the percentage of Str. pneumoniae was higher (11% 
vs 4%). This may be due to the short incubation period of Str. pneumoniae, which 
resulted that they were less missed.  
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7 CONCLUSIONS 
The characteristics and outcome of a bacteraemia, the importance of the underlying 
diseases in deaths of patients with bacteraemia, and the association of cfDNA and 
PCSK9 with the severity of the bacteraemia can be concluded as follows: 
 
1. Blood culture-positive patient in ED has day 7, day 28 and day 90 all-cause 
mortality of 9%, 14% and 20%, respectively. 
2. Underlying diseases have a major role in bacteraemia mortality. Malignancies 
are the most common underlying diseases associated with mortality. Patients with 
bacteraemia who die within 90 days die mostly either of bacteraemia weakening a 
patient with a rapidly fatal underlying disease, or the underlying disease itself. The 
bacteraemia-related deaths of patients without rapidly fatal underlying disease occur 
mostly within 7 days, but they still represent minority in all deaths by day 7. 
3. CfDNA, in contrast to CRP, has value in the prognosis of a patient with 
bacteraemia. Especially when it is combined to positive qSOFA it finds patients with 
high risk of death. DIC resulting in amputations was common among patients with 
the highest level of cfDNA. 
4. PCSK9 was upregulated in bacteraemic infections. Cases with more severe 
disease had a lower level of PCSK9 compared to cases with less severe disease. 
Patients that died had the lowest level, but still higher than the level in healthy 
patients. PCSK9 resembled an acute phase reactant because the expression was 
induced in these bacteraemic infections, it correlated significantly with CRP, and the 
level was lower in cases with liver disease. 
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8 SUMMARY 
In summary, around one third of the cases had qSOFA score of ≥2. Ca. 10% needed 
care in high dependency units and another 10% were treated in ICUs. The 
percentage of people that died shortly after the bacteraemia was quite high (9% by 
day 7), but even the use of this day 7 endpoint does not mean that these patients 
died of infection. Also, deaths by this endpoint are mostly reflecting the fact that 
bacteraemia is a common complication of fatal underlying diseases. The endpoint of 
90 days should be avoided in sepsis studies as it is almost completely reflecting other 
deaths than the deaths that are directly related to the infection. The endpoint of in-
hospital mortality should be avoided as well. 
Both this study and previous results have shown that cfDNA is a prognostic 
biomarker. Within the current cohort, there were few deaths where infection itself, 
instead of underlying diseases, played a major role. The main reason why some of 
these few died was that their bacteraemic sepsis was complicated with DIC. 
Measuring cfDNA might someday aid clinicians in ED in the diagnosis of this 
complication.  
The current results indicate, in contrast to some of the previous studies, that a 
higher level of PCKS9 in bacteraemic patients is not associated with more severe 
disease. In this study those that die after a bacteraemia have a lower level of PCSK9 
on the day of admission compared to all bacteraemic patients. It was also showed 
that PCSK9 resembled acute phase reactants. Studies done with 
hypercholesterolemia patients have shown that blocking of PCSK9 enzyme lowers 
the LDL-cholesterol level and reduces the risk of cardiovascular disease. The answer 
to the question whether or not this blocking improves the survival of sepsis patients 
remains open.  
One explanation why there were so few deaths attributable to sepsis might be 
that they receive such good care in the study hospital (and probably other hospitals 
in the western world). Some of the patients die, for example, from the devastating 
complications of sepsis, i.e. DIC, but otherwise patients that have a prognosis, and 
have been admitted to ED early enough, survive. In general, there might not be 
much room for improvement in sepsis survival. However, this will remain so only if 
there are effective antibiotics in the future as well.  
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11 APPENDIX 
Tiedonkeruulomake 
 
Mikrobiologien osuus 
 
Nimi, löydös, seurantanäyte jne 
1) Koodi 
2) ww-numero 
3) Nimi 
4) Sosiaaliturvatunnus 
5) Aika milloin veriviljelynäyte otettu (muodossa pp.kk.vvvv  kk:kk) 
6) Mikrobin nimi 
7) Fimlabin käyttämä mikrobikoodi 
8) Aika milloin ensimmäinen plasmanäyte otettu (sama muoto kuin yllä) 
9) Milloin 1. seurantanäyte otettu 
10) Milloin 2. seurantanäyte otettu 
11) Milloin 3. seurantanäyte otettu 
12) Milloin 4. seurantanäyte otettu 
13) Milloin 5. seurantanäyte otettu 
14) Mikrobiologien huomautukset 
 
Kliinikon osuus 
 
Perustiedot 
15) Ikä veriviljelyn ottohetkellä 
16) Sukupuoli 
 0 Mies 
 1 Nainen 
Perussairaudet (0=ei, 1=kyllä) 
17) Potilaan sairauskertomuksessa maininta muistisairaudesta, oireisesta aiemmasta 
aivoinfarktista tai aivoverenvuodosta tai muusta etenevästä aivosairaudesta kuten MS-
taudista 
18) Krooniset vaskulaariset sairaudet MCC, ASO, IC (ei pelkkä HA) 
19) Tunnettu läppävika, tekoläppä tai aiempi endokardiitti 
20) Pitkäaikainen keuhkosairaus ml. astma, COPD, fibroosit jne 
21) Pitkäaikainen reumatautisairaus ml. RA, SLE jne 
22) Pitkäaikainen maksasairaus mm. kirroosi, PBC, NASH, mutta ei pelkkä virushepatiitti 
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23) Pitkäaikainen munuaissairaus: HD- tai PD-hoidossa, krea edeltävästi yli 120 tai dU-Prot 
yli 1 g 
24) Potilas sairastaa DM ja mitä tyyppiä (pl. IGT tai IFG) 
 0 Ei 
 1 DM tyyppi 1 
 2 DM tyyppi 2 
 3 DM tyyppi epäselvä tai muu (esim LADA) 
25) Alkoholin aiheuttamisia sosiaalisia tai medisiinisiä ongelmia viimeisen 12 kk aikana 
26) Muiden päihteiden (mm. kannabis, buprenorfiini, amfetamiini, bentosodiatsepiini) 
aiheuttamia sosiaalisia tai medisiinisiä ongelmia viimeisen 12 kk aikana 
27) Potilas sairastaa tai on sairastanut solidia maligniteettia 
28) Jos kyllä, onko maligniteetti metastasoitunut paikallisia imusolmukkeita pidemmälle? 
29) Jos kyllä, mikä maligniteetti kyseessä? (vapaa teksti) 
30) Potilas sairastaa tai on sairastanut hematologista maligniteettia 
31) Tiedossa oleva MRSA kantaja edeltävästi 
32) Tiedossa oleva ESBL kantaja edeltäväst 
33) McCabe luokitus 
 0 Terve 
 1 Ei-fataali perussairaus 
 2 Ultimately fatal (ennuste 0,5-5 v) 
 3 Rapidly fatal (ennuste <0,5 v) 
34) Muut olennaiset tiedot: elin- tai kantasolusiirto, HIV, plasmafereesi, KPC tmv kantaja, 
perna poistettu, hypogamma, tiedossa oleva infektoitunut vierasesine jne (vapaa teksti) 
 
Lääkitys (0=ei, 1=kyllä) 
35) Potilas on saanut solunsalpaajalääkitystä tai immunosupressanttia (siirrännäispotilaat) 
edeltävän 12 kk aikana 
36) Potilas on saanut biologista lääkitystä edeltävän 12 kk aikana (TNF-salp ja kaikki muut 
vastaavat) 
37) Potilaalla oli sairaalaan tullessa kortisonilaakitys, joka vastaa > tai = 5 mg prednisolonia 
38) Potilaalla oli sairaalaan tullessa jokin muu DMARD-lääke kuin yllämainitut 
39) Potilaalla oli antibiootti (ml. sieni- ja viruslääkitys) sairaalaan tullessa 
40) Jos kyllä, mikä antibiootti oli kyseessä (kirjoita numero) 
 1 Amoksilliini, ampisilliini, pivmesillinaami 
 2 Fenoksimetyylipenisilliini ja vastaavat iv/im muodot 
 3 Kloksasilliini ja vastaavat 
 4 Amoxin comp ja vastaavat 
 5 Tazocin ja vastaavat 
 6 1. polven kefalosporiini 
 7 2. polven kefalosporiini 
 8 3. polven kefalosporiini 
 9 Karbapeneemi 
 10 Trimetopriimi 
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 11 Sulfonamidin ja trimetopriimin yhdistelmä 
 12 Makrolidi 
 13 Klindamysiini 
 14 Aminoglykosidi 
 15 Fluorokinoloni 
 16 Vankomysiini 
 17 Metronidatsoli 
 18 Nitrofurantoiini 
 19 Linetsolidi 
 20 Daptomysiini 
 21 Sienilääkitys 
 22 Viruslääkitys 
 23 Tetrasykliini, doksisykliini, tigecycliini 
41) Jos enemmän kuin yhden ab käyttö, mikä on tämä toinen valmiste (samat numerot kuin 
yllä) 
42) Muuta olennaista tai huomioitavaa lääkityksestä (esim saanut kasvutekijää tai IVIG-l
 ääkitystä edeltävästi tai APC:tä hoidon aikana) (vapaa teksti) 
42A) Potilaalla on merkintä statiinin käytöstä ensiapuun tullessa 
42B) Potilaan statiini oli 
1= Simvastatiini 
2=Atorvastatiini 
3=Pravastatiini 
4=Rosuvastatiini 
5=fluvastatiini 
42C) Potilaan statiinin annos (milligrammoissa) 
 
Tietoja Acutan käynnistä, erityisesti keltainen kaavake 
43) Mistä potilas tulee  
 0 Kotoa 
 1 Palvelutalosta, vanhainkodista tmv 
 2 Tk-vuodeosastolta tai muusta sairaalasta 
 3 Epäselvää 
44) Tulohetki Acutaan (muodossa pp.kk.vvvv  kk:kk) 
45) Matalin Acutan tulopäivän systolinen verenpaine (mmHg) 
46) Ym. syst verenpaineen diastolinen arvo (mmHg) 
47) Jos ym syst arvo on >90 eikä vasopressoreiden tarvetta onko potilaalla silti yli 30 mmHg 
syst lasku ja yli 20 mmHg diast lasku 
48) Potilaan korkein mitattu lämpö Acutan tulopäivänä (lukema yhden desimaalin tark) 
49) Jos potilaalla oli alle 36 asteen lämpö, mikä oli lukema (lukema yhden desimaalin tark) 
50) Potilaan korkein mitattu hengitystiheys Acutan tulopäivänä 
51) Potilaan korkein mitattu syke Acutaan tulopäivänä (lukema) 
52) Jos potilaalla oli mitattu a-astrup tulopäivänä, mikä oli pCO2  (X,XX kPa) 
spontaanihengityksellä 
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53) Jos potilaalla oli mitattu a-astrup tulopäivänä, mikä oli laktaatti (X,X mmol/l) 
54) Potilaan henkinen tila Acutan tulopäivänä 
 0 Orientoitunut (GCS puheosuus 5/5 pist) 
 1 Desorientoitunut (GCS puheosuus 4/5 pist) 
 2 Tokkurainen (=Stuporous, alentunut tajunta, ääntelyä tai irrallisia sanoja, 2-3/5 pist) 
 3 Tajuton (=Comatose, ei ääntelyä, 1/5 pist) 
55) Oliko potiaalla neutropenia (alle 1 10E9/l) Acutaan tulopäivänä 
56) Acutaan tulopäivänä potilaalla sairauskertomuksessa merkintä 
  -Kirjavasta ihosta 
  -Heikentyneestä kapillaaritäytöstä 
  -DIC:stä 
  -Heikentyneestä virtsan tulosta <0,5 ml/kg 
  -ARDS:stä 
  -Sydämen uudesta systolisesta dysfunktiosta 
  -Akuuttista tajunnan häiriöstä 
  -EEG häiriöstä 
  -Laktaatti on yli sairaalan viitearvon 
  -Trombopenia alle 100 
57) Jos kyllä, mikä/mitkä oli(vat) kyseessä tai muu olennainen statuslöydös esim MOF tai 
sydänpysähdys ilman menehtymistä (vapaa teksti) 
58) Täyttyykö potilaalla septinen shokki –kriteeri: Persistoivasti syst RR alle 90 TAI MAP 
alle 60 mmHg TAI yli 40 mmHg lasku perustasosta JA Lasku asianmukaisesta 
nesteresuskitaatiosta huolimatta JA Ei muita syitä verenpaineen laskulle  
59) Annettiinko potilaalle sepsiksen tai sen epäilyn vuoksi kortisonia 
 0 Ei 
 1 Iv-hydrokortisonia sepsiksen vuoksi 
 2 Aiemman kortisoniannoksen nosto 
 3 Po- tai iv-kortisonia muulla indikaatiolla esim. heng ahd 
60) Potilaalle aloitettiin antibiootti tulotekstin tai keltaisen kaavakkeen perusteella 
tulopäivänä   
61) Jos kyllä, mikä ab oli kyseessä (kirjoita numero, samat kuin kohta 40) 
62) Jos potilaalle aloitettiin toinenkin antibiootti, mikä ab alkoi (nro) 
63) Jos kyllä, mikä oli ensimmäisen antibiootin aloitushetki (muodossa pp.kk.vvvv  kk:kk) 
64) Mihin potilas siirtyi Acutasta (ml. PTO), kirjoita numero (kirjoita 1, jos pt siirtyi nopeasti 
vo tai valv kautta teholle)  
 1 Teho 
 2 KARA, KARB, SPÄI-valvonta, KEI1-valvonta, GAS-valvonta, VALS-valvonta 
 3 Muu vuodeosasto 
 4 Kotiin 
 5 Kuoli ensiavussa 
 
Tietoja jatkotapahtumista 
65) Potilas joutui respiraattoriin 
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66) Potilas joutui infektion non-invasiiviseen ventilaatiooon (ei aiempaa kotikäyttöä) 
67) Potilas tarvitsi noradrenaliinia, adrenaliinia, dopamiinia tai dobutamiinia 30 vrk sisään 
viljelystä 
 0 Ei 
 1 Noradrenaliinia 
 2 Dopamiinia 
 3 Dobutamiinia 
 4 Kombinaatiota, muuta tai epäselvää, mitä sai 
68) Potilas joutui dialyysiin, kehitti DIC:n, ARDS:n, MOF:n tai muun vakavan 
infektiokomplikaation 30 vrk:n kuluttua viljelystä (empyeemat tmv abcessit poislukien) 
69) Jos potilas menehtyi, mikä oli kuolinpäivä (muodossa pp.kk.vvvv) 
 
Pohdinta 
70) Kliinikon arvio infektiofokuksesta jälkeenpäin CDC nosocomial jaottelu pl. 
disseminoitunut, BSI ja bronkiitti ja lisättynä avoin/tuntematon 
 0 Avoin/tuntematon 
 1 Virtsatiet 
 2 Kirurgisen haavan infektio, ml vierasesineiden infektiot ja prostatabiopsiat 
 3 Pneumonia 
 4 Luiden, bursien ja nivelten infektio, ml epidur abc  
 5 Hermoston infektiot 
6 Cardiovaskulaarisen systeemin infektiot, ml endokardiitti, mediastiniitti ja suonten 
infektiot 
 7 KNK, SUU tai SIL-alan infektiot, ml sinuiitti, faryngiitti 
 8 GI-alan infektiot ml. suolisto, sappitieperäinen ja peritoniitti 
 9 Lisääntymiselinten infektiot 
 10 Iho,ml. ruusu, selluliitti, nekrotisoiva faskiitti, mastiitti ja ihonalainen paise 
71) Kliinikon arvio toisesta infektiofokuksesta (samat numerot kuin yllä) 
72) Kliinikon arvio onko kyseessä terveydenhuollon toimintayksikön antamaan hoitoon 
liittyvä infektio 
73) Muuta erityistä huomioitavaa tästä potilaasta (vapaa teksti) 
 
Laboratoriokokeet 
Vv-hetki on päivä 0 ja 1. 2. 3. ja 4. seurantapäivä 
74) Päivän 0 ensimmäinen kokonaisleukosyyttimäärä 
75) Päivän 1 ensimmäinen kokonaisleukosyyttimäärä 
76) Päivän 2 ensimmäinen kokonaisleukosyyttimäärä 
77) Päivän 3 ensimmäinen kokonaisleukosyyttimäärä 
78) Päivän 4 ensimmäinen kokonaisleukosyyttimäärä 
79) Onko potilaalla päivinä 0-4 trombosyytit alle 100 
 0 Ei  
 1 Kyllä 
 2 Ei tutkittu 
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80) Päivän 0 ensimmäinen CRP-arvo 
81) Päivän 1 ensimmäinen CRP-arvo 
82) Päivän 2 ensimmäinen CRP-arvo 
83) Päivän 3 ensimmäinen CRP-arvo 
84) Päivän 4 ensimmäinen CRP-arvo 
85) Onko potilaalla päivinä 0-4 laktaatti yli sairaalan viitealueen 
 0 Ei 
 1 Kyllä 
 2 Ei tutkittu 
86) Muuta huomioitavaa laboratoriotutkimuksista (vapaa teksti) 
87) Päivien 0-4 ensimmäinen prokalsitoniini 
88) Milloin prokalsitoniini otettu 
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S U M M A R Y
Objective: Few studies have sought to establish how often death after sepsis is related to the sepsis and
how often underlying diseases have a major role in case fatality.
Methods: In this retrospective cohort study, data were collected on 497 cases with blood culture-positive
sepsis in an emergency department (ED).
Results: Sepsis was categorized as severe in 31% of cases; 7% had septic shock. The quick Sepsis-related
Organ Failure Assessment score was positive in 136 out of 473 cases (29%). Ninety-eight patients died by
day 90; in 16 of these cases (16%) the death was sepsis-related in a patient without a rapidly fatal
underlying disease, in 45 cases (46%) the death was sepsis-related in a patient with a rapidly fatal
underlying disease, and in 37 cases (38%) the death was unrelated to sepsis. Sepsis-related death occurred
in 58 out of 61 cases (95%) by day 28.
Conclusions: Underlying diseases were found to have a considerable role in the death of patients suffering
from blood culture-positive sepsis in an ED of a developed country, as only 16% of the deaths by day
90 occurred where death was sepsis-related and the patient had a life-expectancy of more than 6 months.
Improving the outcome of sepsis with new treatments is thus challenging. It is possible that day 7 + day
28 mortality is a more appropriate endpoint than day 90 mortality when studying the outcome of sepsis,
as this time-span includes most of the patients whose death was related to sepsis.
© 2017 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Introduction
Sepsis is one of the leading causes of death worldwide. It has
been ranked as the eleventh most common cause of death in the
USA.1 Advanced age, immunosuppression, diabetes, and cancer are
major risk factors for sepsis.2–6 Prognostic factors for the severity
and outcome of sepsis include advanced age, type of infection (e.g.,
methicillin-resistant Staphylococcus aureus (MRSA), polymicro-
bial), number of organ dysfunctions, and adequacy of antimicrobial
therapy.7–9
Studies have been performed on sepsis patients in emergency
departments (EDs) and intensive care units (ICUs) in order to
determine risk factors for mortality9–13 and the aetiology of
illness.14 Less attention has been paid to the questions of how often
these patients actually die of sepsis, how often sepsis is a
contributory factor in the death of a patient with an advanced
underlying disease, and how often the death is independent of
sepsis.
In this retrospective cohort study, data were collected on 497
adult cases of blood culture-positive sepsis in the ED of Tampere
University Hospital (TAUH). A categorization of causes of death was
developed in order to establish how often death was related to
sepsis in patients without a rapidly fatal underlying disease (group
1), was related to sepsis by weakening of a patient with a rapidly
fatal underlying disease (group 2), and was independent of sepsis
but caused by the underlying disease (group 3). It was also sought
to determine the best cut-off among the commonly used days for
mortality used in sepsis research, i.e. day 7, day 28, or day 90, for
mortality related to sepsis (deaths in groups 1 and 2).
Materials and methods
TAUH is a tertiary hospital with a catchment population of
approximately 524 700 inhabitants in Pirkanmaa County. The ED of
* Corresponding author. Tel: +358 3 31166747, Fax: +358 3 31164333.
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the hospital handles patients requiring both basic and specialized
emergency care. In specialized care, the majority of patients are
internal medicine and surgical patients. Blood cultures are taken
routinely from patients with signs or symptoms of systemic
infection. The population of the present study comprised 497 adult
patients admitted to the ED of TAUH and treated in specialized
care, who had blood culture-positive sepsis during the period
March 1, 2012 to February 28, 2014. The study was approved by the
Ethics Committee of Tampere University Hospital. The need for
informed consent was waived, as no additional blood sampling
was needed and routine patient care was not modiﬁed.
TAUH has a 24-bed ICU which includes a seven-bed high
dependency unit (HDU). In this article, ‘ICU’ refers to both of these.
There are four other HDUs (cardiology, pulmonary, surgical, and
internal medicine), all taking care of sepsis patients; these are
referred to as ‘HDUs’.
Blood cultures were collected in BacT/Alert Aerobic (FA Plus)
and Anaerobic (FN Plus) blood culture bottles and placed in the
automated microbial detection system BacT/Alert 3D (bioMérieux,
Marcy l’Etoile, France). All patients with a positive blood culture
obtained during specialized care in the ED were identiﬁed in the
microbiology laboratory serving TAUH (Fimlab Laboratories plc).
Patient details, the name of the organism, and the date of blood
culture were collected by clinical microbiologists (T.S. and J.A.).
Cultures positive for coagulase-negative Staphylococcus, Propio-
nibacterium, Micrococcus, Bacillus, and Corynebacterium, with
detection in a single blood culture bottle and without clinical
relevance, were considered to be contaminants and were excluded.
Patients whose routine blood samples taken on admission were
no longer available for further studies were also excluded. This
could be due, for example, to the fact that the blood culture became
positive later than 72 h after the day of admission.
The clinical data for the patients included in the study were
gathered retrospectively from the patient records by the principal
investigator (J.R.). The site of infection was decided retrospectively
by the principal investigator based on clinical judgement. Sepsis
was deemed to be healthcare-associated if the symptoms had
started more than 48 h after admission to a healthcare institution,
or the bacteraemia was related to a surgical operation within the
preceding 30 days or some other invasive procedure within the
previous 10 days.15 Data on cause of death were gathered from
patient records (and autopsy records when applicable) by two
clinicians (J.R. and R.H.) independently. In cases of discrepancy, a
meeting was held together with a third clinician (J.S.) and a ﬁnal
decision was made.
Cause of death by day 90 was classiﬁed into three different
categories: (1) group 1 included cases of sepsis-related mortality in
patients without a rapidly fatal underlying disease. The immediate
cause of death in this group was sepsis, or sepsis was a factor in a
chain of events leading to death, and the patient had a life-
expectancy of more than 6 months. (2) Group 2 included cases of
sepsis-related mortality in patients with a rapidly fatal underlying
disease. In this group, the patient died of sepsis (immediate cause
of death, or sepsis was a factor in a chain of events leading to death)
by weakening of a patient with a rapidly fatal (<6 months)
underlying disease. (3) Group 3 included cases of mortality related
to underlying disease. In this group, sepsis was not an immediate
cause of death or a factor in a chain of events leading to death.
The categorization was based on clinical decision and the
judgement was based on the severity of the patient’s underlying
disease, the patient’s pre-performance, severity of the sepsis, and
recovery after the infection. The main underlying disease
associated with death was determined retrospectively by the
principal investigator.
Diagnoses of sepsis, severe sepsis, and septic shock were made
according to consensus deﬁnitions.16 Further, the quick Sepsis-
related Organ Failure Assessment score (qSOFA) was calculated
post-hoc according to recently published deﬁnitions.17 The qSOFA
score was positive if at least two of the following three criteria
were fulﬁlled in the ED: respiratory rate 22/min, altered
mentation, and systolic blood pressure 100 mmHg. The McCabe
classiﬁcation was determined as reported by McCabe and
Jackson.18 The Pitt bacteraemia score was calculated as presented
by Korvick et al.19 IBM SPSS version 22.0 software (IBM Corp.,
Armonk, NY, USA) was used for the statistical analyses. Categorical
data were analyzed by Chi-square test, or Fisher’s exact test when
appropriate. Odds ratios (OR) with 95% conﬁdence intervals (95%
CI) are also presented.
Results
There were 800 consecutive positive blood cultures in adult
patients during the study period. One hundred and thirty-six of
these were considered to be contaminants and 167 were excluded
for other reasons. A total 497 cases of positive blood culture
among 484 patients were thus included. All 497 cases had sepsis.
During the study period, 11 patients had sepsis twice on different
admissions and one patient had sepsis three times. Of the total
study population, 262 (53%) were male and 235 (47%) were
female; they ranged in age from 16 to 95 years (median 68 years).
Table 1 provides the demographic data, data on the causative
organisms, and data on the underlying diseases stratiﬁed into six
different categories: groups 1, 2, and 3 (as noted in the Materials
and methods section), all patients who died, all patients who
survived, and all cases. For 16 out of 98 patients (16%) who died by
day 90, death was related to sepsis and the patient did not have a
rapidly fatal underlying disease (group 1), i.e. 3% of all 497 sepsis
cases. For 45 patients (46% of all deaths by day 90), death was
related to sepsis in that it weakened the patient leading to the
death, which was in any case expected as the patient had a rapidly
fatal underlying disease (group 2). For 37 patients (38%), death by
day 90 was unrelated to sepsis and was caused by an underlying
disease(s) in the patient (group 3).
Of the group 1 patients, four (25%) had alcohol abuse as an
underlying disease (Table 1). One was without any underlying
disease. Four of the patients in group 1 were over 80 years of age
(25%). Three group 1 patients (19%) were found lying at home with
a low level of consciousness and were transferred to hospital. In
group 2 patients, the rapidly fatal underlying disease was a solid
tumour with metastasis in eight cases (18%) and a haematological
malignancy in nine (20%). In group 3 patients, the cause of death
was a solid tumour with metastasis in 19 patients (51%) and a
haematological malignancy in two (5%). Thus, malignancies were
associated with death in 46% of patients in groups 2 and 3
combined. Other common rapidly fatal underlying diseases
associated with death among the patients in groups 2 and 3 were
liver disease (11%), heart disease (11%), and neurological/neuro-
surgical disease (10%).
The case fatality rate by day 7, day 28, and day 90 was 9%, 14%,
and 20%, respectively. Death occurred by day 7 in 94% of group 1
patients, in 56% of group 2 patients, and in 11% of group 3 patients
(Figure 1). All except two cases in group 2 died before day 28. The
deaths in group 3 occurred most often between day 29 and day 90
(68%). Ninety-ﬁve per cent of all sepsis-related deaths occurred
within 28 days after sepsis.
Table 2 gives data on the severity of sepsis stratiﬁed into the
same categories as used in Table 1. The qSOFA was positive in 136
out of 473 cases (29%). Group 1 had the highest Pitt bacteraemia
scores. Forty-eight (10%) cases were transferred from the ED to the
ICU and 52 (11%) to HDUs. Thus, the majority of sepsis patients and
the majority of qSOFA-positive cases were taken care of in general
wards. Out of 449 cases who were treated outside the ICU, 104
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(23%) had severe sepsis and nine (2%) had septic shock. Of those
with septic shock, three died in the ED and the remainder had
underlying diseases that had progressed too far for them to beneﬁt
from treatment in the ICU.
By site of infection, the most common infection was urinary
tract infection (131 cases, 26%), followed by intra-abdominal
infection (84 cases, 17%), infection of the skin, soft tissues, and
bones (72 cases, 15%), and lower respiratory tract infection
(54 cases, 11%). The site of infection was unknown in 118 cases
Table 1
Characteristics underlying diseases, and causative organisms in relation to the outcome.
Sepsis-related mortality in
patients without a rapidly
fatal underlying disease
(Group 1) (n = 16)
Sepsis-related mortality
in patients with a rapidly
fatal underlying disease
(Group 2) (n = 45)
Mortality related to
underlying disease
(Group 3) (n = 37)
All patients who
died (n = 98)
Patients who
survived
(n = 399)
All cases
(N = 497)
n (%) n (%) n (%) n (%) n (%) n (%)
Median age, years (range) 77 (51–94) 78 (42–93) 70 (44–91) 74 (42–94) 68 (16–95) 68 (16–95)
Male sex 8 (50) 24 (53) 25 (68) 57 (58) 205 (51) 262 (53)
Underlying diseases
Heart disease 8 (50) 23 (51) 10 (27) 41 (42) 135 (34) 176 (35)
Diabetes mellitus, any type 6 (38) 15 (33) 13 (35) 34 (34) 105 (26) 139 (28)
Neurological 5 (31) 14 (31) 9 (24) 28 (29) 84 (21) 112 (23)
Solid tumour with
metastasisa
1 (6) 10 (22) 17 (46) 28 (29) 29 (7) 57 (12)
Alcohol abuseb 4 (25) 5 (11) 8 (22) 17 (17) 35 (9) 52 (11)
Liver disease 3 (19) 8 (18) 6 (16) 17 (17) 32 (8) 49 (10)
Haematological malignancy 0 (0) 11 (24) 4 (11) 15 (15) 30 (8) 45 (9)
No underlying diseases 1 (6) 0 (0) 0 (0) 1(6) 70 (14) 71 (14)
Causative organismc
Gram-positive 5 (31) 18 (40) 13 (35) 36 (37) 189 (47) 225 (45)
Gram-negative 9 (56) 19 (42) 14 (38) 42 (43) 181 (45) 223 (45)
Escherichia coli urosepsis 3 (19) 6 (13) 3 (8) 12 (12) 85 (21) 97 (20)
Polymicrobial and anaerobes 2 (13) 8 (18) 10 (27) 20 (20) 28 (7) 48 (10)
a The most common solid tumour with metastasis was cancer of the gastrointestinal tract (36 cases).
b Social or medical problems of alcohol abuse in the past 12 months.
c Excluding fungi (n = 1).
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Figure 1. Number of cases in groups 1, 2, and 3 in relation to day of case fatality in a total of 98 patients who died within 90 days after sepsis. The percentage is per category of
cause of death.
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(24%). Sepsis was healthcare-associated in 81 patients (16%). The
previous use of immunosuppressive medications was common:
94 (19%) patients were taking corticosteroids (any dose) and 56
(11%) were on cancer chemotherapy. Antibiotics were started on
the day of admission in 93% of patients. The most common
antibiotic was cefuroxime (57%), followed by ceftriaxone (18%)
and ﬂuoroquinolone (11%). An antibiotic combination was
started in 16% of patients. The median time from admission to
the start of antibiotics was 174 min (range 0–1269 min).
Of all cases, 426 (86%) had one or more underlying diseases. As
shown in Table 1, there were signiﬁcantly more alcohol abusers in
group 1 as compared to those who survived for more than 90 days
(4/16 vs. 35/399; OR 3.8, 95% CI 1.2–12.4, p = 0.04). There were also
signiﬁcantly more patients with a solid tumour with metastasis
and patients with haematological malignancies among those who
died by day 90 than among survivors (28/98 vs. 29/399, OR 5.1, 95%
CI 2.9–9.1, p < 0.01 and 15/98 vs. 30/399, OR 2.2, 95% CI 1.1–4.3,
p = 0.02, respectively).
The causative organisms are listed in Table 3. Gram-positive and
Gram-negative organisms were equally common. There were few
cases with MRSA and extended-spectrum beta-lactamase-produc-
ing Enterobacteriaceae and no cases with vancomycin-resistant
enterococci or carbapenemase-producing Enterobacteriaceae.
Discussion
In this study, the case fatality rate by day 7, day 28, and day
90 was 9%, 14%, and 20%, respectively, in 497 cases with blood
culture-positive sepsis treated in an ED. The day 7 and day 28 case
fatality rates in this study are similar to those reported in a study by
Lin et al., who also studied bacteraemic patients in the ED.9 In two
other studies investigating the day 28 case fatality rate in
bacteraemic patients in the ED, Lee et al. reported a rate of 9%
and Kao et al. reported a rate of 19%.12,20
Only 16% of all deaths by day 90 in the present study were
related to sepsis in patients with a life-expectancy of more than 6
months (group 1). Forty-six percent of deaths occurred in patients
with a rapidly fatal underlying disease although death was sepsis-
related (group 2), and 38% of deaths were related to the underlying
disease (group 3). It is known that underlying diseases have a role
in the deaths of sepsis patients,2–4,9 but the categorization of the
present study gives a picture of the signiﬁcance of the underlying
diseases in these deaths.
Even patients in group 1 had many factors contributing to
death, for example alcoholism or very old age. There was only one
patient in this group without any underlying disease. It is possible
that there were patients in group 1 who sought treatment too late,
as three patients in this group were found lying at home with a low
level of consciousness. There were also signiﬁcantly more alcohol
abusers as compared to those who survived more than 90 days.
Altogether, in this cohort consisting mostly of community-
acquired cases seen in a university hospital ED in a developed
country, there were few non-survivors who would have had a life-
expectancy of more than 6 months and who might have beneﬁted
from a novel drug directed against sepsis or septic shock. This may
also explain why so many clinical trials in the ﬁeld of sepsis have
failed.21
Day 90 mortality has been used as the endpoint in many sepsis
studies.22–24 However, the present study showed that most (95%)
of the patients whose death was sepsis-related died within 28 days
after sepsis, while the majority of deaths occurring between day 28
Table 2
Severity of the sepsis in relation to the outcome.
Sepsis-related mortality in
patients without a rapidly fatal
underlying disease (Group 1)
(n = 16)
Sepsis-related mortality in
patients with a rapidly fatal
underlying disease (Group 2)
(n = 45)
Mortality related to
underlying disease
(Group 3) (n = 37)
All patients who
died (n = 98)
Patients who
survived (n = 399)
All cases
(N = 497)
n (%) n (%) n (%) n (%) n (%) n (%)
Severe sepsis 16 (100) 30 (67) 13 (35) 59 (60) 93 (23) 152 (31)
Septic shock 9 (56) 9 (20) 4 (11) 22 (22) 15 (4) 37 (7)
qSOFA-positivea 13 (81) 26 (59) 16 (46) 55 (58) 81 (21) 136 (29)
Admitted from ED to
ICU
11 (69) 7 (16) 3 (8) 21 (21) 27 (7) 48 (10)
Pitt bacteraemia scoreb
0–1 1 (6) 16 (36) 20 (57) 37 (39) 269 (68) 306 (62)
2–3 3 (19) 17 (39) 10 (29) 30 (32) 93 (24) 123 (25)
4 12 (75) 11 (25) 5 (14) 28 (29) 33 (8) 61 (12)
ED, emergency department; ICU, intensive care unit; qSOFA, quick sepsis-related organ failure assessment.
a Data available for 473 cases (95 who died and 378 who survived).
b Data available for 490 cases.
Table 3
Causative organisms.
Organisms n (%)
Gram-positive 225 (45.3)
Staphylococcus aureus 74 (14.9)
MRSA 3 (0.6)
Coagulase-negative Staphylococcus 11 (2.2)
Streptococcus pneumoniae 52 (10.5)
b-haemolytic streptococci 45 (9.1)
Viridans streptococci 21 (4.2)
Enterococci 17 (3.4)
Other Gram-positive 5 (1.0)
Gram-negative 223 (44.9)
Escherichia coli 159 (32.0)
ESBL-E. coli 9 (1.8)
Klebsiella sp 21 (4.2)
ESBL-Klebsiella sp 0 (0.0)
Pseudomonas aeruginosa 18 (3.6)
Other Gram-negative 25 (5.0)
Others 49 (9.9)
Anaerobes 15 (3.0)
Fungi 1 (0.2)
Polymicrobial 33 (6.6)
All 497 (100)
MRSA, methicillin-resistant Staphylococcus aureus; ESBL, extended-
spectrum beta-lactamase.
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and day 90 were independent of sepsis. This makes day 28 a more
appropriate time-point to investigate sepsis-related mortality, as
regulatory agencies have indeed considered.21 Nonetheless, only
34% of deaths occurring between day 0 and day 7 were sepsis-
related in patients with a life-expectancy of more than 6 months.
Thus, even when day 7 and day 28 are used as endpoints for sepsis
mortality, deaths independent of sepsis are not ruled out.
This study has some limitations. By reason of the study design,
it was not possible to include all blood culture-positive cases
admitted to the ED during the study period. The potential
representativeness of the material was assessed by reviewing
the blood culture ﬁndings of those cases that were not included in
the study. Altogether there were 167 such cases (contaminants
excluded). The percentages of the most common blood culture
ﬁndings, S. aureus and Escherichia coli, did not differ between the
study population and the cases that were not included. It is thus
unlikely that missed cases would have had a major impact on the
results. Among cases not included in the material as compared to
those included, the percentage of anaerobes and other Gram-
negative organisms (see Table 3) was somewhat higher (9.0% vs.
3.0% and 10.2% vs. 5.0%, respectively) and the percentage of
Streptococcus pneumoniae was lower (4.2% vs. 10.5%). This may be
due to the long incubation period of anaerobes and other Gram-
negative organisms and the short incubation period of S. pneumo-
niae. Again, assuming that case fatality among missed cases with
anaerobes or other Gram-negatives would be approximately the
same as among those included in the study, the numbers would be
too low to alter the major ﬁndings of the study.
Only blood culture-positive cases were included, which would
exclude for example those with false-negative blood cultures. This
might also have led to a lower number of septic patients with
respiratory infection. However, it is also a strength that culture-
negative sepsis cases, which are difﬁcult to deﬁne, were not
included. Hence the material consists more of true infections than
patients who were for example only positive for systemic
inﬂammatory response syndrome (SIRS).
The material was gathered in a tertiary level hospital of a
developed country with a low incidence of multi-resistant
bacteria. These types of results cannot, therefore, be generalized
to low-income countries, as has been pointed out by Rello and
Leblebicioglu.25 It is possible that the role of the underlying
diseases would also have been different if the study patients had
been only from ICUs.
The method used to categorize the cause of death was
developed by the authors. It encompasses the classiﬁcation used
on the death certiﬁcate (immediate cause and underlying cause)
and combines it with the McCabe classiﬁcation of rapidly fatal
disease. This has limitations, since in some cases it was not easy to
decide whether the patient would have lived for more than 6
months without the sepsis or not. Even group 1 patients were
elderly and had many underlying diseases. However, the authors
believe that the categorization used is illustrative of the course of
events among these patients, and the use of two or three clinicians
to provide a judgement gives it sufﬁcient validity.
In conclusion, this study showed that patients with sepsis who
die within 90 days after sepsis in a developed country, die mostly
either of sepsis by weakening of the patient with a rapidly fatal (<6
months) underlying disease, or of the underlying disease itself.
This does not mean that sepsis patients do not need high-quality
care. Indeed, the low number of cases of sepsis-related mortality
among patients with a life-expectancy of more than 6 months may
be attributed to the good quality of the care these patients
received. When investigating sepsis-related mortality, day
28 should be used as the endpoint to identify most of the
sepsis-related mortality, while a large part of sepsis-independent
mortality is ruled out.
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Abstract. Rannikko J, Seiskari T, Huttunen R,
Tarkiainen I, Jylh€av€a J, Hurme M, Syrj€anen J,
Aittoniemi J (Tampere University Hospital; Univer-
sity of Tampere; Fimlab Laboratories, Tampere,
Finland; Biostatistics, Karolinska Institute,
Stockholm, Sweden) Plasma cell-free DNA and
qSOFA score predict 7-day mortality in 481 emer-
gency department bacteraemia patients. J Intern
Med 2018; https://doi.org/10.1111/joim.12766
Background. A few studies have shown that both quick
Sequential Organ Failure Assessment (qSOFA)
score and cell-free DNA (cfDNA) have potential use
as a prognostic marker in patients with infection.
We studied these two markers alone and in combi-
nation to identify those emergency department (ED)
patients with the highest risk of death.
Methods. PlasmacfDNA levelwasstudiedondays0 to4
after admittance to the ED from 481 culture-positive
bloodstream infection cases. The qSOFA score was
evaluated retrospectively according to Sepsis-3 def-
initions. The primary outcome was death by day 7.
Results. CfDNA on day 0 was signiﬁcantly higher in
nonsurvivors than in survivors (2.02 lg mL1 vs.
1.35 lg mL1, P < 0.001). CfDNA level was high
(>1.69 lg mL1) in 134 (28%) of 481 cases, and the
qSOFA score was ≥2 in 128 (28%) of 458 cases.
High cfDNA and qSOFA score ≥2 had 70% and 77%
sensitivity and 76% and 76% speciﬁcity in predict-
ing death by day 7, respectively. High cfDNA alone
had odds ratio (OR) of 7.7 (95% CI 3.9–15.3) and
qSOFA score ≥2 OR of 11.6 (5.5–24.3), but their
combination had OR of 20.3 (10.0–41.4) in pre-
dicting death by day 7 when compared with those
with low cfDNA and qSOFA score <2. Amongst the
ﬁve cases with the highest cfDNA levels, there were
three patients with severe disseminated intravas-
cular coagulation.
Conclusion. CfDNA and qSOFA score can be used
independently to identify those bacteraemia
patients at high risk of death, and combining these
two markers gives additional advantage.
Keywords: bacteraemia, biomarker, sepsis.
Introduction
Cell-free plasma DNA (cfDNA), also called extracel-
lular DNA, comprises fragments of DNA that are
released from apoptotic and necrotic cells [1]. Ele-
vated levels of cfDNA in blood have been found in
various clinical conditions, such as cancer, trauma,
stroke and sepsis [2–5]. A few studies have indicated
that cfDNA may have value in predicting the mor-
tality of sepsis patients in intensive care units (ICUs)
[3, 6–11] and in emergency department (ED)
patients [12, 13]. In recent years, cfDNA has also
been found to have a role as a link between innate
immunity and coagulation [14], and increased levels
of cfDNA are found in patients with deep vein
thrombosis [15]. To the best of our knowledge, no
studies have evaluated cfDNA as a possible marker
of disseminated intravascular coagulation (DIC).
The criteria for sepsis were recently changed, and
the quick Sequential Organ Failure Assessment
(qSOFA) score has been introduced [16]. The qSOFA
score was not invented to replace systemic inﬂam-
matory response syndrome (SIRS), but instead to
help identify patients with suspected infection out-
side ICUs who are likely to develop complications
[17, 18]. The qSOFA score has been shown to be
better than SIRS as a prognostic marker of in-
hospital mortality in an ED setting [19].
In our earlier study, we evaluated 497 cases with
blood culture-positive infection in the ED to
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establish how often death was related to sepsis and
how often underlying diseases played a major role
[20]. In this study, we have measured plasma
cfDNA in 481 of these blood culture-positive infec-
tion cases and evaluated the use of cfDNA as a
prognostic marker in addition to the qSOFA score.
We have also evaluated the possible association of
high cfDNA to the clinical characteristics of bac-
teraemia. We used death by day 7 as a primary
end-point, as in our earlier study, most of the
sepsis-related deaths in patients with a prognosis
of more than 6 months occurred early after admit-
tance to the ED. Our secondary end-point was
death by day 28.
Methods
Tampere University Hospital is a tertiary hospital
situated in the Pirkanmaa region of Finland with a
catchment population of approximately 524 700
inhabitants. Blood cultures are routinely taken
from patients with signs or symptoms of systemic
infection. As described in our previous study [20],
blood culture-positive cases in the specialized care
ED of Tampere University Hospital were selected
during the period 1 March 2012 to 28 February
2014. In this study, all cases with an available
plasma sample for cfDNA analysis were included.
The clinical data of the patients were gathered
retrospectively. The primary and secondary end-
points were death by day 7 and day 28, respec-
tively.
Blood cultures were collected in BacT/Alert aerobic
(FA Plus) and anaerobic (FN Plus) blood culture
bottles and placed in an automated microbial
detection system BacT/Alert 3D (bioMerieux,
Marcy l’Etoile, France). All culture-positive cases
were selected by a clinical microbiologist. Cultures
positive for coagulase-negative Staphylococcus,
Propionibacterium, Bacillus, Micrococcus and
Corynebacterium, with detection in a single blood
culture bottle and without clinical relevance, were
considered to be contaminants and were excluded.
Also, positive samples were excluded if the ﬁrst
routine blood sample within the ﬁrst 24 h after the
blood culture collection (day 0) was missed. This
could be because the culture became positive later
than 72 h after admission.
The level of plasma cfDNA was analysed from
blood samples from days 0 to 4. The day 0
sample was gathered mostly at the same time as
the collection of the blood cultures, but samples
gathered within 24 h of the collection were
included. Qubit dsDNA HS Assay Kit and Qubit
2.0 ﬂuorometer (Invitrogen, Carlsbad, CA, USA)
were used for quantiﬁcation of plasma cfDNA.
The manufacturer’s instructions and protocols
were followed at each step. After plasma extrac-
tion, the turnaround time spent on the laboratory
analysis of cfDNA level was approximately
10 min. The intra-assay coefﬁcients of variation
from control samples were between 3.55% and
5.73%. The ﬁnal result was the average of the two
samples.
Diagnoses of sepsis, severe sepsis and septic shock
were made according to Sepsis-2 consensus deﬁ-
nitions [21]. A criterion for qSOFA score was
calculated based on Sepsis-3 deﬁnitions [16]. The
qSOFA score comprises the following criteria:
altered mentation, respiratory rate ≥22 and systolic
blood pressure ≤100 mmHg. In this study, altered
mentation was classiﬁed based on the verbal
section of the Glasgow Coma Scale: if the patient
had less than 5 points in this section, the patient
was considered to have altered mentation. The Pitt
Bacteraemia Score was calculated as presented by
Korvick et al. [22].
IBM SPSS version 22.0 software (IBM Corp.,
Armonk, NY, USA) was used for the statistical
analyses. A P-value of <0.05 was considered sig-
niﬁcant. Nonparametric data were analysed by
Mann–Whitney U-test or Kruskal–Wallis test when
appropriate. The Youden index was used to select
optimal cut-off analysis. Predictive performance
(accuracy) of the cfDNA level and qSOFA score was
assessed using the AUC/ROC statistic. A logistic
regression model was used to study the indepen-
dent effect of high cfDNA level on mortality models
adjusted for potential confounders. The survival
curve was assessed using the Kaplan–Meier
method, and survival differences between groups
were compared by log-rank test. The study was
approved by the Ethics Committee of Tampere
University Hospital and the National Supervisory
Authority for Welfare and Health. The need for
informed consent was waived as no additional
blood sampling was needed and routine patient
care was not modiﬁed.
Results
There were 800 consecutive positive blood cultures
during the study period. Contaminants (n = 136)
were excluded, and 167 blood cultures were
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excluded for missing the blood sample from day 0.
The ﬁrst sixteen of the gathered samples went
missing later. A total of 481 cases amongst 469
patients were thus included. There were 253 (53%)
male cases, 228 (47%) female cases, all were adults
(>16 years), and the median age was 68 years.
Table 1 provides information on patient character-
istics, clinical presentation and microbiology of the
infection.
The minimum cfDNA level on day 0 to day 4 was
0.72 lg mL1, and the maximum was 66.95
lg mL1. The mean level on day 0 was 1.73
lg mL1, and the median was 1.38 lg mL1.
Table 2 and Fig. 1 show levels of cfDNA during
days 0 to 4 in all cases and in relation to death by
day 7. CfDNA day 0 levels in the nonsurvivors were
signiﬁcantly higher compared with survivors. Fur-
thermore, levels remained at a signiﬁcantly higher
level on day 1 to day 4.
The optimal cut-off value for the plasma cfDNA
values on day 0 in predicting death by day 7 was
estimated using ROC curve, as illustrated in
Fig. 2. CfDNA had an AUC of 0.77 (95% CI 0.69
to 0.85) in predicting death by day 7. A cut-off
value of 1.69 lg mL1 had sensitivity of 70.4%
and speciﬁcity of 76.4% in predicting death by day
7 with an AUC of 0.73 (95% conﬁdence interval
(CI) 0.65 to 0.82, P < 0.001). Plasma cfDNA levels
above this cut-off value are hereafter referred to as
high and levels below this value are referred to as
low. CfDNA level was high in 134 (28%) of 481
cases, and qSOFA score was ≥2 in 128 (28%) of
458 cases. A comparison of high cfDNA and
qSOFA score ≥2 in relation to death by day 7 is
given in Table 3. QSOFA score ≥2 together with
high cfDNA level on day 0 resulted in a 20-fold
risk of death by day 7, when compared with those
with low cfDNA level and qSOFA score <2. Odds
ratios of death by day 7 were 7.7 (95% CI 3.9 to
15.3) and 11.6 (95% CI 5.5 to 24.3) for high vs.
low cfDNA and qSOFA score ≥2 vs. qSOFA score
<2, respectively (Table 3). Figure 3 presents the
Kaplan–Meier survival curves by day 28 for high
cfDNA, qSOFA score ≥2 and both.
Death by day 28 was a secondary end-point.
CfDNA on day 0 was signiﬁcantly higher in
nonsurvivors than in survivors (1.95 lg mL1 vs.
1.33 lg mL1, P < 0.001). CfDNA had an AUC of
0.76 (95% CI 0.69 to 0.82) in predicting
death by day 28. The optimal cut-off value of
cfDNA in predicting death by day 28 was the same
Table 1 Patient characteristics, clinical presentation and
microbiological data of the study population
Data
Demographic
Cases/Patients 481/469
Patients admitted twice/three times 10/1
Gender (female/male)) 228/253
Median age, y (range) 68 (16–95)
Chronic medical condition n (%)
Coronary artery disease,
chronic vascular disease
or chronic heart failure
155 (32)
Diabetes mellitus 137 (29)
Social or medical problems
of alcohol abuse
49 (10)
Solid tumour with metastasis 55 (11)
Haematological malignancy 45 (9)
Severity of the sepsis n (%)
Sepsis 481 (100)
Severe sepsis (≥1 organ failure) 145 (30)
Septic shock 36 (8)
qSOFA score ≥2a 128 (28)
Case transferred from ED to ICU 44 (9)
Site of infection n (%)
Urinary 134 (28)
Intra-abdominal 83 (17)
Skin, soft tissue and bones 71 (15)
Pulmonary 48 (10)
Unknown 116 (24)
Causative organism n (%)
Gram-positive 213 (44)
Staphylococcus aureus 71 (15)
Streptococcus pneumonia 46 (11)
Gram-negative 222 (46)
E. coli 156 (32)
Others 46 (10)
Anaerobes 15 (3)
Fungi 1 (0.2)
Polymicrobial 30 (6)
Day of case fatality n (%)
Days 0 to 7 44 (9)
Days 0 to 28 69 (14)
Days 0 to 90 97 (20)
qSOFA, quick Sequential Organ Failure Assessment; ED,
emergency department; ICU, intensive care unit.
aData available on 458 cases.
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as in death by day 7 (1.69 lg mL1). The results
for the secondary end-point (day 28) are shown in
Table 3.
The maximum level of cfDNA at day 0 was
38.85 lg mL1, and in this patient, it remained
between 29.50 lg mL1 and 66.95 lg mL1 on
days 1 to 4. This patient suffered from a severe
pneumococcal infection with DIC resulting in mul-
tiple amputations. Amongst the ﬁve highest cfDNA
levels at day 0, there were two other patients with
DIC caused by Capnocytophaga canimorsus sepsis
that resulted in skin necrosis or amputations.
Table 2 Plasma cell-free DNA (cfDNA) levels during days 0 to 4 after admission to emergency department in all cases and in
relation to death by day 7
Days after admission
Plasma cfDNA (lg mL1), median (quartiles)
P-valuesAll Nonsurvivors Survivors
Day 0 1.38 (1.20–1.77) 2.02 (1.51–2.92) 1.35 (1.19–1.66) <0.001
Day 1 1.36 (1.18–1.73) 2.20 (1.57–3.63) 1.33 (1.17–1.64) <0.001
Day 2 1.35 (1.16–1.65) 1.87 (1.59–2.92) 1.33 (1.16–1.61) <0.001
Day 3 1.33 (1.16–1.61) 1.81 (1.48–4.34) 1.32 (1.14–1.58) <0.001
Day 4 1.35 (1.17–1.71) 1.66 (1.49–2.38) 1.33 (1.15–1.68) 0.017
Maximum value 1.49 (1.28–1.91) 2.24 (1.56–4.55) 1.45 (1.27–1.81) <0.001
cfDNA values available on 481 patients on day 0, 446 patients on day 1, 389 patients on day 2, 300 patients on day 3, 137
patients on day 4 and 481 patients on days 0 to 4 (maximum value).
Fig. 1 A line plot diagram showing cell-free DNA (cfDNA)
levels during days 0 to 4 after admission to emergency
department in 44 patients who died by day 7 (black plots)
and 437 survivors (open plots). One case with all cfDNA
levels over 30 lg mL1 excluded from the ﬁgure. *Cut-off,
cfDNA value of 1.69 lg mL1 had an optimal sensitivity of
70.4% and speciﬁcity of 76.4% in predicting day 7
mortality from the day 0 sample based on the AUC-ROC-
analysis.
Fig. 2 Receiver operating characteristic (ROC) curve on
plasma cell-free DNA level, qSOFA score ≥2 and both
cfDNA>1.69 lg mL1 and qSOFA score ≥2 measured on
day of admission to the emergency department in relation
to case fatality by day 7.
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Their cfDNA levels were 9.65 lg mL1 and
8.92 lg mL1.
Median level of cfDNA at day 0 in cases with qSOFA
score <2 was 1.34 lg mL1 (interquartile range
(IQR) 1.16 lg mL1 to 1.64 lg mL1). Ten patients
with qSOFA score <2 died by day 7 with the median
day 0 cfDNA level of 1.45 lg mL1 (IQR
1.38 lg mL1 to 1.90 lg mL1). The difference of
day 0 cfDNA level between survivors and nonsur-
vivors in patients with qSOFA score <2 was statis-
tically insigniﬁcant (P = 0.10). C-reactive protein
(CRP) level on day 0 did not have a signiﬁcant
predictive value for death by day 7 (AUC 0.52 (95%
CI 0.43 to 0.60), P = 0.677, data on 478 cases). In
predicting transfer to ICU within 24 hours of
admission, cfDNA level had an AUC of 0.70 (95%
CI 0.61 to 0.80, P < 0.001) and qSOFA score ≥2
0.72 (0.63 to 0.80, P < 0.001).
Table 4 presents the day 0 plasma cfDNA levels
stratiﬁed by various demographic features, under-
lying conditions and severity of sepsis. The level of
cfDNA was statistically signiﬁcantly higher in
the following conditions: liver disease, alcohol
abuse, septic shock, admitted from ED to ICU,
Pitt Bacteraemia Score ≥4 and death by day 7 or
day 28. The level of cfDNA was statistically sig-
niﬁcantly lower in patients with haematologic
cancer.
Statistically signiﬁcant variables associated with
death by day 7 in univariate analysis were cardio-
vascular disease, liver disease, alcohol abuse,
MRSA carriage, Pitt Bacteraemia Score ≥4, high
cfDNA, qSOFA score ≥2 and both qSOFA score ≥2
and high cfDNA. The following variables were not
associated with death by day 7: sex, age over 60,
age over 80, neurological disease, pulmonary dis-
ease, rheumatological disease, kidney disease,
substance abuse (other than alcohol), metastatic
tumour, haematological malignancy, ESBL car-
riage, gram stain result, E.coli urosepsis or CRP
over 100 mg L1 on the ﬁrst day. The odds ratios of
death by day 7 for high cfDNA, qSOFA score ≥2 and
both adjusted for these variables were 7.7 (95% CI
3.9 to 15.3), 11.6 (95% CI 5.5 to 24.3) and 21.3
(95% CI 10.5 to 43.5), respectively. In multivariable
analysis, we included all statistically signiﬁcantly
associated variables in univariate analysis. QSOFA
score ≥2, high cfDNA, qSOFA score ≥2 combined
with high cfDNA, cardiovascular disease and Pitt
Bacteraemia Score ≥4 remained signiﬁcant in this
model.Ta
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Discussion
The present study shows that qSOFA score and
cfDNA identify patients with a high risk of death
due to bacteraemia infection. In this study, 34 of
128 (27%) patients with qSOFA score ≥2 in the ED
had died by day 7. If the patients had both qSOFA
score ≥2 and cfDNA of more than 1.69 lg mL1 on
day 0, 47% of them died. Thus, the combination of
high cfDNA level and qSOFA score ≥2 elevated the
risk of death by day 7 from 12-fold to 20-fold.
QSOFA has recently been shown to predict organ
failure and in-hospital mortality in 1009 patients
with suspected infection [23]. Yet, the authors
recommended the use of further conﬁrmatory test.
Given the present results, the combination of
qSOFA score ≥2 and high cfDNA does not improve
sensitivity in predicting death by day 7, but it could
be an option to further improve speciﬁcity. As an
illustration, we suggest a two-step approach where
qSOFA score ≥2 is followed by cfDNA analysis: in
the present material comprising 458 sepsis cases,
qSOFA score ≥2 results in 128 cases at higher risk
of death due to bacteraemia infection during the
ﬁrst week. Analysing the cfDNA of these 128
exposes 57 cases with even higher 7-day mortality
of 47%. Moreover, the turnaround time spent on
laboratory analysis of cfDNA level was approxi-
mately 10 min (after plasma extraction). This does
not make turnaround time a signiﬁcant obstacle
for clinical use, but due to the need for plasma
extraction, no point-of-care test is yet available
The Sepsis-3 task force did not ﬁnd relevant
change in predictive validity when lactate was
added to qSOFA [24]. Clinicians will continue
measuring lactate as the result is a numerical
value rather than just the value of positive or
negative. Especially high levels of lactate are seen
in patients with severe infections, and the kinetics
of lactate has been shown to have value in the
prognosis of sepsis patients [25]. In this study,
especially high levels of cfDNA were seen in
patients with DIC that resulted in amputations.
This is not surprising as a growing body of evidence
suggests a role for cfDNA and DNA-binding pro-
teins in the pathogenesis of DIC [14]. Because
there were only few patients with DIC in our
material, further studies are needed to establish
cfDNA as an early marker for DIC. Nevertheless,
this ﬁnding also suggests that cfDNA could be an
option to identify those patients with severe con-
sequences of sepsis.
The AUC of cfDNA in predicting death by day 7 and
day 28 was 0.77 and 0.76, respectively. These are
somewhat lower than in two studies carried out in
ED with soluble urokinase-type plasminogen acti-
vator receptor (suPAR) [26, 27]. These studies had
an AUC of 0.79 and 0.84 in predicting death by day
30. When using their cut-off values, suPAR seems
to be more sensitive in predicting death (76% and
83% vs. 65%) and cfDNA has a slightly better
speciﬁcity (69% and 76% vs. 78%). In another
cfDNA study carried out by our group, these
predictors are more or less the same as in the
Fig. 3 Cumulative day 28 survival in culture-positive cases with (a) maximum plasma cell-free DNA (cfDNA) >1.69 lg mL1
compared with those with cfDNA ≤1.69 lg mL1, (b) qSOFA score ≥2 compared with those with qSOFA score <2 and (c)
cfDNA >1.69 and qSOFA score ≥2 compared with those with cfDNA ≤ 1.69 lg mL1 and qSOFA < 2. The survival curve was
calculated using the Kaplan–Meier method, and survival differences between groups were compared by log-rank test.
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suPAR studies (AUC 0.84, sensitivity 83% and
speciﬁcity 76%) [12]. As the biochemical mecha-
nism of these two markers differs greatly, it is
possible that these markers perform differently
depending on the subgroups within septic patients.
Cases with suspected DIC might be one subgroup
where cfDNA could be of help.
This study has some limitations. Our study was a
single-centre tertiary hospital study comprising
mostly community-onset infections. Furthermore,
our material comprises only culture-positive cases,
so one has to be cautious when extrapolating these
results to culture-negative cases with infection. In
addition, 167 of the culture-positive cases were
excluded as the routine blood sample from day 0
was missed. However, the microbiological data of
these missed cases were analysed and we did not
ﬁnd any differences that would have altered the
ﬁndings of this study [20].
In line with previous studies [28–30], the results of
the present study show that CRP-level has no value
in predicting fatality. A high level of CRP (or
leucocytes) is still an important sign for clinicians;
at least they have to think could the patient have
an infection or sepsis. When sepsis is suspected, a
clinician in the ED has to decide, for example,
whether the patient needs care in the ICU. A recent
study suggested that only clinical impression of
condition might be used to make this decision [31],
but occasionally clinicians might need some extra
Table 4 Day of admission plasma cell-free DNA (cfDNA) values stratiﬁed by various demographic features, underlying
conditions and severity of sepsis
Plasma cfDNA (lg mL1) on day of admission to emergency department
P-valueFactor present, median (quartiles) Factor absent, median (quartiles)
Characteristics and underlying conditions
Male 1.42 (1.24–1.85) 1.30 (1.16–1.64) 0.002
Age over 60 years 1.39 (1.22–1.80) 1.32 (1.16–1.60) 0.035
Age over 80 years 1.46 (1.25–1.89) 1.35 (1.18–1.69) 0.020
Cardiovascular disease 1.40 (1.22–1.75) 1.36 (1.19–1.82) 0.822
Diabetes any type 1.38 (1.18–1.70) 1.36 (1.20–1.77) 0.894
Chronic kidney diseasea 1.38 (1.26–1.73) 1.36 (1.19–1.77) 0.561
Liver disease 1.91 (1.41–2.15) 1.35 (1.19–1.67) <0.001
Alcohol abuseb 1.95 (1.47–2.38) 1.34 (1.18–1.64) <0.001
Solid tumour with metastasis 1.51 (1.20–1.97) 1.36 (1.19–1.71) 0.142
Haematologic cancer 1.27 (1.12–1.68) 1.37 (1.22–1.76) 0.041
Gram-positive bacteraemiac 1.35 (1.17–1.67) 1.38 (1.23–1.80) 0.180
Polymicrobial infection 1.58 (1.25–2.13) 1.36 (1.19–1.75) 0.058
Severity of sepsis
qSOFA score ≥2d 1.56 (1.26–2.20) 1.34 (1.16–1.64) <0.001
Severe sepsis 1.61 (1.31–2.23) 1.31 (1.17–1.60) <0.001
Septic shock 1.96 (1.32–2.83) 1.36 (1.19–1.70) <0.001
Admitted from ED to ICU 1.95 (1.40–2.89) 1.35 (1.19–1.69) <0.001
Pitt Bacteraemia Score ≥4e 1.83 (1.34–2.73) 1.35 (1.19–1.68) <0.001
Death by day 7 2.02 (1.51–2.92) 1.35 (1.19–1.66) <0.001
Death by day 28 1.95 (1.50–2.58) 1.33 (1.18–1.64) <0.001
ED, emergency department; ICU, intensive care unit.
aHistory of creatinine more than 120 μmol L1.
bSocial or medical problems of alcohol abuse in the past 12 months.
cExcluding polymicrobial (n = 30) and anaerobical (n = 15) bacteraemia.
dData available on 458 cases.
eData available on 474 cases.
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help in making these decisions. Therefore, count-
ing qSOFA score and measuring the level of cfDNA
might help the decision-making process.
In conclusion, the present study shows that the
combined information on qSOFA score and cfDNA
can identify patients with the highest risk of death
due to bacteraemia infection. These markers may
ﬁnd those patients admitted to ED with the highest
need of care.
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